{"meta":{"query_hash":"5ce50c55e25f","filters":{"venue":"Immunotherapy"},"cohort_total":51,"direct_labels_cover":0,"predictions_cover":51,"exported":51,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5ce50c55e25f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Immunotherapy"},"results":[{"id":"W1979255880","doi":"10.2217/imt.10.44","title":"Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy","year":2010,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Immunotherapy; Dendritic cell; Immunology; Viral vector; Immune system; Cancer immunotherapy; Antigen; Biology; Antigen-presenting cell; T cell; Autoimmunity; Cytotoxic T cell; Medicine; In vitro; Recombinant DNA","score_opus":0.018322650537083374,"score_gpt":0.3438783695124331,"score_spread":0.32555571897534974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979255880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036918053,0.99333614,0.0007620024,0.000016648157,0.00018872762,0.0016328613,0.00008513145,0.000023270386,0.00026340593],"genre_scores_gemma":[0.0021295464,0.9950554,0.00033504592,0.00008220175,0.00020593341,0.0010357258,0.00044524585,0.00023347765,0.00047744554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704254,0.0003920382,0.000934953,0.00070528494,0.00034183386,0.00058333285],"domain_scores_gemma":[0.9977569,0.0000831467,0.0004455109,0.0015342678,0.0001153791,0.00006478196],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006083378,0.00059912435,0.0011851811,0.00051401654,0.00009680943,0.000041428837,0.0010987073,0.00073005294,0.00014312145],"category_scores_gemma":[0.0000136128765,0.0005736932,0.00078810315,0.0006081885,0.00024103171,0.0000061872906,0.000062935804,0.00074396183,0.00003934997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034064625,0.00034095772,0.000025217552,0.0011741429,0.00015707422,0.000002464397,0.00003306069,0.000011685307,0.12085473,0.000012985459,0.00003618206,0.8770109],"study_design_scores_gemma":[0.0013347345,0.0008321439,0.0000062360486,0.0006657135,0.00003590399,0.000005063315,0.000011142786,0.000007729664,0.034669705,0.000021677719,0.9618714,0.0005385671],"about_ca_topic_score_codex":0.00005471327,"about_ca_topic_score_gemma":0.00013470587,"teacher_disagreement_score":0.9618352,"about_ca_system_score_codex":0.00007431122,"about_ca_system_score_gemma":0.0008125421,"threshold_uncertainty_score":0.99967146},"labels":[],"label_agreement":null},{"id":"W1982443638","doi":"10.2217/imt.14.108","title":"Lentiviral Vectors in Cancer Immunotherapy","year":2015,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Canada Research Chairs; University of Toronto","funders":"","keywords":"Immunotherapy; Viral vector; Cancer immunotherapy; Cancer; Insertional mutagenesis; Immune system; Genetic enhancement; Vector (molecular biology); Medicine; Computational biology; Gene delivery; Effector; Clinical trial; Biology; Immunology; Cancer research; Bioinformatics; Gene; Genome; Genetics","score_opus":0.03454148207282977,"score_gpt":0.34331361838432595,"score_spread":0.3087721363114962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982443638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777226,0.02046283,0.00010614542,0.00038604526,0.0003566857,0.00031760902,0.000010920574,0.00004555274,0.00059163384],"genre_scores_gemma":[0.9925969,0.0041839927,0.00011835466,0.00092572626,0.00028250553,0.0001586508,0.00003371474,0.00012434546,0.0015757792],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837023,0.00019147733,0.0002693621,0.00039571818,0.00028969208,0.00048349553],"domain_scores_gemma":[0.99913645,0.0000107597725,0.000068706315,0.0005981961,0.00010067548,0.00008518809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052298914,0.0002380659,0.00021946993,0.00013040456,0.000041852025,0.0000452613,0.0004396749,0.00016854581,0.00008384739],"category_scores_gemma":[0.000018067618,0.00022535014,0.000118192416,0.00025882456,0.00011834488,0.000010147999,0.000047972135,0.00018643834,0.000038995615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005322959,0.00018177646,0.010214078,0.0000033218544,0.00011895803,0.0000057893503,0.0003686644,0.0001922917,0.936711,0.000030881587,0.001378924,0.04547137],"study_design_scores_gemma":[0.008045159,0.004311217,0.0076493835,0.00002873598,0.0000035498801,0.00000907193,0.00017929211,0.000114893744,0.7592673,0.0003256907,0.21943666,0.00062909274],"about_ca_topic_score_codex":0.00047467495,"about_ca_topic_score_gemma":0.0008578037,"teacher_disagreement_score":0.21805774,"about_ca_system_score_codex":0.00010778256,"about_ca_system_score_gemma":0.00033269942,"threshold_uncertainty_score":0.9189512},"labels":[],"label_agreement":null},{"id":"W1993673970","doi":"10.2217/imt.14.122","title":"Bidirectional Interactions of NK Cells and Dendritic Cells in Immunotherapy: Current and Future Perspective","year":2015,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada)","funders":"","keywords":"Crosstalk; Immunotherapy; Immune system; Tumor microenvironment; Cancer immunotherapy; Dendritic cell; Innate immune system; Biology; Acquired immune system; Cell biology; Immunology; Physics","score_opus":0.025132914531614585,"score_gpt":0.3209390407875841,"score_spread":0.2958061262559695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993673970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000373052,0.9867992,0.000025062272,0.000044014716,0.011340665,0.0006849981,0.00007096695,0.00004709562,0.0006149421],"genre_scores_gemma":[0.00012963453,0.9958876,0.000036028156,0.000038634636,0.00018804318,0.0001045346,0.00011521633,0.00007398907,0.003426329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763215,0.0005572459,0.00085942016,0.0005498735,0.00007381299,0.00032752543],"domain_scores_gemma":[0.99860054,0.0002482915,0.00051796564,0.00037572338,0.00022888219,0.00002859879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034162027,0.0005494204,0.0014487699,0.0006863456,0.0001328022,0.00004274089,0.00019628757,0.0004646657,0.00069728703],"category_scores_gemma":[0.0000111847085,0.0004757709,0.00032536229,0.00032575938,0.00027640053,0.00022145352,0.00005919881,0.0011845003,0.00014419122],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029566156,0.00039624597,0.0000067541505,0.00094660715,0.0007051448,0.0000021336382,0.0016140373,2.6067045e-7,0.019773604,0.0005062571,0.0025260963,0.9732272],"study_design_scores_gemma":[0.0013874936,0.00020680315,0.000022476848,0.0018747804,0.00010495146,0.00020514974,0.00096532446,0.0000011220083,0.0012091771,0.00006017098,0.99356335,0.00039917338],"about_ca_topic_score_codex":0.00025495765,"about_ca_topic_score_gemma":0.000024161263,"teacher_disagreement_score":0.9910373,"about_ca_system_score_codex":0.00035375767,"about_ca_system_score_gemma":0.000245529,"threshold_uncertainty_score":0.9997694},"labels":[],"label_agreement":null},{"id":"W2007718183","doi":"10.2217/imt.13.81","title":"Ustekinumab for the Treatment of Crohn‘s Disease","year":2013,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Genentech; ActoGeniX; Zalicus; Janssen Biotech; Wyeth","keywords":"Ustekinumab; Medicine; Crohn's disease; Psoriasis; Monoclonal antibody; Disease; Immunology; Immune system; Monoclonal; Crohn disease; Inflammatory bowel disease; Antibody; Tumor necrosis factor alpha; Internal medicine; Adalimumab","score_opus":0.09589915221036092,"score_gpt":0.41507802521478165,"score_spread":0.3191788730044207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007718183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004374121,0.9919026,0.00009656829,0.000082448954,0.00023900495,0.0073821256,0.00009998921,0.000028683793,0.00012482647],"genre_scores_gemma":[0.000007575712,0.9835545,0.00015959318,0.000047647012,0.00038067508,0.0031786258,0.00010097332,0.00012688144,0.012443544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982812,0.00007323539,0.00058743986,0.00033053843,0.00035041463,0.00037717153],"domain_scores_gemma":[0.9969922,0.0010658483,0.00025755417,0.0014274297,0.00013734757,0.00011966899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014387438,0.00040280263,0.0016042558,0.000116832605,0.000081525424,0.0000323072,0.00033161332,0.0001815013,0.00048593263],"category_scores_gemma":[0.00004408205,0.000189704,0.0013528015,0.00018687763,0.00020155103,0.000027050159,0.000018360854,0.0001150386,0.00012776408],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003883885,0.00034786522,2.4866682e-7,0.007483382,0.0013796375,0.000030774852,0.0001035834,3.450962e-7,0.0000011518838,0.00011252556,0.0011391948,0.9890129],"study_design_scores_gemma":[0.009538817,0.0006377037,0.0000089521845,0.003318058,0.0011324483,0.000044820586,0.00001027518,0.00019869934,0.0000053992317,0.000022092896,0.984927,0.00015575686],"about_ca_topic_score_codex":0.00033720987,"about_ca_topic_score_gemma":0.000002205715,"teacher_disagreement_score":0.98885715,"about_ca_system_score_codex":0.008232607,"about_ca_system_score_gemma":0.00928878,"threshold_uncertainty_score":0.99632764},"labels":[],"label_agreement":null},{"id":"W2043429701","doi":"10.2217/imt.13.141","title":"Employing an IL-23 p19 Vaccine to Block IL-23 Ameliorates Chronic Murine Colitis","year":2013,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Colitis; Medicine; Immunology; In vivo; Interleukin 23; Splenocyte; Pathogenesis; Inflammatory bowel disease; In vitro; Peptide vaccine; Interleukin; Antibody; Cytokine; Disease; Internal medicine; Epitope; Biology","score_opus":0.006629204937353886,"score_gpt":0.248728499099141,"score_spread":0.2420992941617871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043429701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972599,0.0010266185,0.00009201438,0.00033183955,0.00023313255,0.00072510366,0.000062884304,0.00007838854,0.00019009243],"genre_scores_gemma":[0.9945684,0.0003934775,0.00041179778,0.0015272519,0.00066135236,0.0002614074,0.00021013846,0.000107775006,0.0018583741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983736,0.00010486235,0.0003366063,0.000492666,0.00016112626,0.00053109793],"domain_scores_gemma":[0.99858814,0.000009329464,0.00009768652,0.0008912469,0.00019700883,0.00021658938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014820372,0.0003123395,0.00022139716,0.00008109171,0.00015267493,0.000113905335,0.00041419477,0.0001602829,0.00034307936],"category_scores_gemma":[0.000024943736,0.00030714265,0.00012135865,0.00012978469,0.00004205671,0.000020735737,0.00009472874,0.000108501765,0.00075855205],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037196305,0.00012515912,0.003626251,0.000025272075,0.00013082867,0.000031070776,0.00015211714,0.00020475754,0.98354316,0.00005783382,0.0048820213,0.0068495683],"study_design_scores_gemma":[0.004391817,0.0017231279,0.52650315,0.00007410156,0.00003044278,0.000044357097,0.0001537232,0.00030842106,0.28940383,0.00022180911,0.17594376,0.0012014972],"about_ca_topic_score_codex":0.00016484498,"about_ca_topic_score_gemma":0.00018326275,"teacher_disagreement_score":0.69413936,"about_ca_system_score_codex":0.00006838726,"about_ca_system_score_gemma":0.0001489785,"threshold_uncertainty_score":0.9999381},"labels":[],"label_agreement":null},{"id":"W2067278548","doi":"10.2217/imt.11.25","title":"Research Highlights: Do Conventional Treatments for HPV-Positive Head and Neck Cancers Elicit Immunotherapeutic Type Responses?","year":2011,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; HPV vaccines; Cancer; Human papillomavirus; Head and neck cancer; MEDLINE; Family medicine; Oncology; Internal medicine; Cervical cancer; HPV infection; Biology","score_opus":0.10979874981573376,"score_gpt":0.4235713409828063,"score_spread":0.31377259116707257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067278548","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060416847,0.19356331,0.00016675834,0.6806299,0.0029388864,0.015893357,0.0020902536,0.00037801327,0.043922644],"genre_scores_gemma":[0.029838271,0.09489745,0.0016707325,0.63355875,0.0106288055,0.0043806876,0.0036505754,0.0012273804,0.22014736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99589044,0.00041571975,0.0005454708,0.0009182009,0.0011139157,0.0011162414],"domain_scores_gemma":[0.99670684,0.0008356956,0.00014851987,0.0008617082,0.0012925338,0.0001547],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007186154,0.00054026116,0.0009086298,0.00064417766,0.0004345921,0.00015117966,0.0003778413,0.0009236589,0.0064652474],"category_scores_gemma":[0.000047387864,0.00043852328,0.00035639002,0.0004761577,0.0006221195,0.00010672254,0.00006941551,0.0019560894,0.00015658353],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09686203,0.0006719447,0.000862599,0.000985473,0.009169399,0.00051690015,0.0020510296,2.7056532e-7,0.005065774,0.0019225742,0.7252121,0.15667993],"study_design_scores_gemma":[0.010851743,0.0052350764,0.02824752,0.00030144575,0.00019681767,0.000060880207,0.00004992264,0.000011599799,0.0011699127,0.0011384058,0.9522993,0.0004373509],"about_ca_topic_score_codex":0.002284859,"about_ca_topic_score_gemma":0.000042083855,"teacher_disagreement_score":0.22708726,"about_ca_system_score_codex":0.0013517224,"about_ca_system_score_gemma":0.0014444235,"threshold_uncertainty_score":0.99980664},"labels":[],"label_agreement":null},{"id":"W2069156224","doi":"10.2217/imt.12.27","title":"Research Highlights: Highlights from the Latest Articles in Immunotherapy","year":2012,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Flora (microbiology); Immunology; Immune system; Autoimmunity; Disease; Gut flora; Biology; Nod; Microbiology; Medicine; Diabetes mellitus; Bacteria; Internal medicine; Genetics","score_opus":0.03316066186204686,"score_gpt":0.31498712821296493,"score_spread":0.28182646635091807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069156224","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2213551,0.06615256,0.000024287066,0.7090917,0.0012008578,0.0010456219,0.00020151823,0.000045625246,0.000882723],"genre_scores_gemma":[0.15063983,0.059170585,0.00051728165,0.7580351,0.017208612,0.00037376056,0.003127236,0.00051865063,0.0104089165],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612635,0.0008827922,0.0006016732,0.0007328081,0.00043653548,0.001219843],"domain_scores_gemma":[0.99764943,0.00025735446,0.00019337749,0.0016816886,0.00016036708,0.000057793484],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000991341,0.00050301314,0.0004730295,0.00017130579,0.00034006752,0.00015706656,0.0012252394,0.0014206641,0.00032075046],"category_scores_gemma":[0.00001765423,0.0003431988,0.00022811789,0.00032237987,0.00035130716,0.000011013187,0.00013172392,0.0019487235,0.00037977973],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001825842,0.000096906726,0.000355034,0.000013420762,0.0001665817,0.00002165923,0.0005601393,8.11981e-7,0.3916046,0.00009872109,0.60574883,0.0011506866],"study_design_scores_gemma":[0.0012072524,0.00018716027,0.008389307,0.000092088645,0.0000079696665,0.000011722924,0.00004961722,9.161679e-7,0.018783439,0.00026589737,0.9705806,0.00042405157],"about_ca_topic_score_codex":0.0031386933,"about_ca_topic_score_gemma":0.00052629603,"teacher_disagreement_score":0.37282115,"about_ca_system_score_codex":0.00012397797,"about_ca_system_score_gemma":0.00033303842,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2070064055","doi":"10.2217/imt.09.80","title":"Immunization of Newborn and Adult Mice with Low Numbers of BCG Leads to Th1 Responses, Th1 Imprints and Enhanced Protection Upon BCG Challenge","year":2009,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Vaccination; Medicine; Immunization; Immunology; Immune system; Context (archaeology); Tuberculosis; Immunity; Biology; Pathology","score_opus":0.013538066028322032,"score_gpt":0.30396912302094264,"score_spread":0.2904310569926206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070064055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910604,0.0012718657,0.0021752215,0.004341462,0.000019470554,0.0008134545,0.0000046601144,0.000024941226,0.00028856436],"genre_scores_gemma":[0.99200165,0.0054559307,0.0018344236,0.00046886478,0.000029105195,0.00002964841,0.000008145044,0.000019271098,0.0001529393],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988473,0.00019281206,0.0003093999,0.00023967586,0.00017443034,0.00023636475],"domain_scores_gemma":[0.99915075,0.00009048491,0.00013112405,0.00030252134,0.00024206644,0.00008304087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039952097,0.00014495697,0.00038755662,0.00016189077,0.00004963599,0.000006460713,0.00007132709,0.00012260165,0.000020218546],"category_scores_gemma":[0.00023080283,0.000111682944,0.00003554309,0.00021964016,0.00009589877,0.0000875862,0.000014888901,0.00018174345,0.0000029269963],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009863529,0.00014374833,0.0017799115,0.000064864464,0.00007619181,0.0000018137023,0.0011865062,0.000008429966,0.84024644,0.000116003845,0.00002095083,0.1464916],"study_design_scores_gemma":[0.0064089247,0.009966977,0.527358,0.0005644843,0.000030807565,0.00007501126,0.00037433283,0.00034535013,0.45340082,0.00020628469,0.0010299281,0.00023910066],"about_ca_topic_score_codex":0.00064859824,"about_ca_topic_score_gemma":0.000108550244,"teacher_disagreement_score":0.5255781,"about_ca_system_score_codex":0.000041036365,"about_ca_system_score_gemma":0.00006234702,"threshold_uncertainty_score":0.45542985},"labels":[],"label_agreement":null},{"id":"W2097078544","doi":"10.2217/imt.12.17","title":"Distinct Roles of Dendritic and B Cells in the Activation of Naive CD4 <sup>+</sup> T Cells","year":2012,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cell biology; Chemistry; Molecular biology; Biology; Immunology","score_opus":0.007320964166931451,"score_gpt":0.24076332085394234,"score_spread":0.23344235668701088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097078544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6840325,0.105879694,0.00009245153,0.000107720734,0.20705451,0.0014695294,0.001048362,0.000052149644,0.00026308018],"genre_scores_gemma":[0.946014,0.019370873,0.00008926778,0.00013465097,0.030432517,0.00017361483,0.0009192367,0.0002004616,0.0026653816],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966826,0.0012316317,0.00097434013,0.0003780329,0.0001948662,0.00053852506],"domain_scores_gemma":[0.99478334,0.0034924853,0.00072641356,0.00079657574,0.00018919277,0.000011997377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00105246,0.000533893,0.0010188906,0.00032892803,0.00014999221,0.000028610066,0.0007888064,0.0012865842,0.00024043067],"category_scores_gemma":[0.0001464917,0.00039686874,0.00026931017,0.00025218332,0.0007581677,0.00018849732,0.000055588276,0.001105881,0.00003788695],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033920489,0.00057373533,0.00008625856,0.00020266537,0.00066770526,0.0000018573269,0.011038081,0.000007650876,0.88159674,0.000111026864,0.0907703,0.011551945],"study_design_scores_gemma":[0.0027945668,0.000496477,0.0007073785,0.00039872888,0.00006955364,0.0000053503913,0.0010872659,0.000001790975,0.3565399,0.000058505386,0.6374894,0.00035112046],"about_ca_topic_score_codex":0.0006561845,"about_ca_topic_score_gemma":0.000016829348,"teacher_disagreement_score":0.5467191,"about_ca_system_score_codex":0.000067569235,"about_ca_system_score_gemma":0.00022891408,"threshold_uncertainty_score":0.9998483},"labels":[],"label_agreement":null},{"id":"W2106760394","doi":"10.2217/imt.09.33","title":"Conference Scene: 3Rd Keystone Symposium On T Regulatory Cells","year":2009,"lang":"en","type":"article","venue":"Immunotherapy","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"T-cell receptor; Biology; Antigen; Immunology; T cell; Immune system","score_opus":0.01104180238505264,"score_gpt":0.23039033689177657,"score_spread":0.21934853450672392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106760394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735211,0.00732822,0.00015044572,0.0028061387,0.0026346443,0.00043195655,0.000020688116,0.00037758105,0.0127291875],"genre_scores_gemma":[0.966902,0.0014394415,0.00010577829,0.003206145,0.00007267049,0.000017916256,0.000054231357,0.000037563557,0.02816423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979704,0.00025694168,0.00045168263,0.0005542987,0.00007400582,0.00069267204],"domain_scores_gemma":[0.9986049,0.000097034885,0.00019279165,0.0009783224,0.000096507305,0.000030430947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024229787,0.00041157586,0.0005026653,0.00017374907,0.0003254248,0.000039094484,0.0006008861,0.0005497319,0.00149306],"category_scores_gemma":[0.0000069957596,0.00035763124,0.00019708234,0.00016426225,0.00038742964,0.0001081327,0.00003354258,0.0005877408,0.0038178856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006696067,0.00047923732,0.00003421709,0.0000041560393,0.00015314625,0.000011637015,0.00041308618,0.000007796395,0.96396655,0.0065693706,0.0057133087,0.02197787],"study_design_scores_gemma":[0.0026595017,0.0011337631,0.0011726654,0.000044086566,0.000015855603,0.000054008025,0.000059156806,0.0000031850723,0.82315797,0.00047213514,0.17084874,0.00037892265],"about_ca_topic_score_codex":0.000053880973,"about_ca_topic_score_gemma":0.0000034811949,"teacher_disagreement_score":0.16513543,"about_ca_system_score_codex":0.00007871236,"about_ca_system_score_gemma":0.00009721655,"threshold_uncertainty_score":0.9998876},"labels":[],"label_agreement":null},{"id":"W2111454565","doi":"10.2217/imt.10.40","title":"T-Cell-Directed Treatment Strategies for Type 1 Diabetes and the Confounding Role of Inflammation","year":2010,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Diabetes and associated disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Type 2 diabetes; Inflammation; Confounding; Medicine; Diabetes mellitus; Type 1 diabetes; Bioinformatics; Immunology; Internal medicine; Biology; Endocrinology","score_opus":0.00426918085693779,"score_gpt":0.2497773023748755,"score_spread":0.24550812151793772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111454565","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7978868,0.030340398,0.000014032541,0.0000708025,0.16931525,0.0011405308,0.00026987147,0.00003390205,0.0009284291],"genre_scores_gemma":[0.45324692,0.053816527,0.0005753258,0.0001044226,0.47434598,0.0009425895,0.012414111,0.0003408246,0.0042133],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993301,0.000044350763,0.00019152237,0.00017789227,0.0000963146,0.00015979921],"domain_scores_gemma":[0.99918264,0.00017698592,0.00024228408,0.00020747159,0.00017687293,0.000013731633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516671,0.0001847859,0.00026204612,0.000024139183,0.000078876496,0.00007266863,0.00012549954,0.0004740012,0.0000063440384],"category_scores_gemma":[0.000089026216,0.00012550723,0.00011101935,0.000034498767,0.00012649424,0.0000037870718,0.000014414098,0.000099940466,9.0914403e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045326859,0.00005023548,0.000058480913,0.00003660514,0.0005536896,2.6403852e-8,0.0003633592,0.000006339035,0.92541516,0.00020541527,0.057771385,0.015086046],"study_design_scores_gemma":[0.0035448645,0.00046492508,0.0000050353397,0.000019068442,0.000056672245,2.235927e-8,0.00024542722,0.0000751545,0.07379601,0.0005585503,0.9210821,0.00015219273],"about_ca_topic_score_codex":0.000060906823,"about_ca_topic_score_gemma":0.00003581671,"teacher_disagreement_score":0.8633107,"about_ca_system_score_codex":0.000010908811,"about_ca_system_score_gemma":0.00018494352,"threshold_uncertainty_score":0.5118036},"labels":[],"label_agreement":null},{"id":"W2133116144","doi":"10.2217/imt.09.40","title":"Immunotherapy as a Strategy for Treatment of Leishmaniasis: a Review of the Literature","year":2009,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Research on Leishmaniasis Studies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Manitoba Health Research Council","keywords":"Leishmaniasis; Medicine; Immunotherapy; Immunology; Intensive care medicine; Drug resistance; Drug; Immune system; Biology; Pharmacology","score_opus":0.0728975426469038,"score_gpt":0.4127452399516908,"score_spread":0.33984769730478703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133116144","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021812093,0.9886117,0.000005153436,0.00072124583,0.0001493087,0.009197622,0.00022826929,0.00003689459,0.0010279911],"genre_scores_gemma":[0.0000074946956,0.9937247,0.0002507545,0.00052147836,0.00020952191,0.0013068031,0.000119293276,0.00015275154,0.0037072012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959966,0.0004123615,0.0017574526,0.00057918014,0.00072956335,0.00052483485],"domain_scores_gemma":[0.9954382,0.0004086493,0.0013473323,0.0020285929,0.00070524105,0.00007195484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005543598,0.00087606383,0.005550913,0.00027499418,0.00012116733,0.000037329224,0.0007085272,0.00041347134,0.00012800207],"category_scores_gemma":[0.0001489102,0.0004540238,0.0037728082,0.0010165737,0.00025420662,0.00007676088,0.00003372747,0.00029879838,0.0000111835425],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003013682,0.0007353181,0.0000021471317,0.09571793,0.0029004626,0.000008902345,0.00032242748,4.649189e-8,0.00006410884,0.00029825768,0.0014183925,0.8982306],"study_design_scores_gemma":[0.001990024,0.003537769,0.000034709614,0.24434322,0.00079552946,0.00014179776,0.000022749988,2.2044588e-7,0.00010042669,0.000091647686,0.74870545,0.00023645232],"about_ca_topic_score_codex":0.00005263047,"about_ca_topic_score_gemma":0.0000036292095,"teacher_disagreement_score":0.89799416,"about_ca_system_score_codex":0.00039076092,"about_ca_system_score_gemma":0.0012919387,"threshold_uncertainty_score":0.99979115},"labels":[],"label_agreement":null},{"id":"W2135975326","doi":"10.2217/imt.14.66","title":"Vedolizumab for Ulcerative Colitis and Crohn’s Disease: Results and Implications of GEMINI Studies","year":2014,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Vedolizumab; Ulcerative colitis; Medicine; Inflammatory bowel disease; Internal medicine; Gastroenterology; Crohn's disease; Placebo; Maintenance therapy; Disease; Immunology; Pathology; Chemotherapy","score_opus":0.014533153546715452,"score_gpt":0.2979342926323513,"score_spread":0.28340113908563586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135975326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953609,0.0029733442,0.0004337084,0.00034626582,0.000039033806,0.0003618487,0.000309117,0.0000071776535,0.00016861258],"genre_scores_gemma":[0.9969239,0.0018084982,0.00044471855,0.000239629,0.000074818476,0.00014086108,0.000059848662,0.000015417589,0.00029226844],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99944955,0.00004282413,0.00016316443,0.00020079201,0.000036231722,0.00010743629],"domain_scores_gemma":[0.9994179,0.00004595405,0.00010281167,0.0002539555,0.0001310578,0.00004830934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012488534,0.00009397732,0.00011049198,0.00001825046,0.0000906098,0.000012311667,0.000059784707,0.000039900606,0.0000011582852],"category_scores_gemma":[0.0001751784,0.00008705756,0.000036990223,0.000017158467,0.00018478095,0.0000035560138,0.000029547431,0.000018507691,3.487411e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06041318,0.0005824985,0.040634267,0.001111558,0.0026919367,0.000019001198,0.0068979375,0.000055431636,0.5340439,0.06962138,0.020545274,0.26338363],"study_design_scores_gemma":[0.0023364776,0.00014775939,0.97193766,0.000021346676,0.000020529682,0.0000019011839,0.00009302868,0.000033221815,0.0038095303,0.0016677341,0.01980391,0.00012688072],"about_ca_topic_score_codex":0.0000027847766,"about_ca_topic_score_gemma":0.000017355216,"teacher_disagreement_score":0.93130344,"about_ca_system_score_codex":0.0000067196725,"about_ca_system_score_gemma":0.000037639016,"threshold_uncertainty_score":0.35501042},"labels":[],"label_agreement":null},{"id":"W2156823146","doi":"10.2217/imt.13.123","title":"Evolution of Oncolytic Viruses: Novel Strategies for Cancer Treatment","year":2013,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Biology; Immune system; Cancer; Virotherapy; Immunotherapy; Virus; Immunology; Immunogenic cell death; Innate immune system; Virology; Cancer research; Genetics","score_opus":0.08584175302475491,"score_gpt":0.41542203599673644,"score_spread":0.3295802829719815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156823146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015649837,0.9941537,0.0012235601,0.000007977485,0.00018586608,0.002368989,0.00040857916,0.000012709221,0.00007366853],"genre_scores_gemma":[0.000120387704,0.9950554,0.00031171006,0.000033939763,0.00034755142,0.002826702,0.00016609844,0.0001221039,0.0010161395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984601,0.000090357156,0.00049654744,0.00044379392,0.00015936431,0.00034981009],"domain_scores_gemma":[0.99869686,0.000045744062,0.00034152486,0.00070265174,0.00016602871,0.000047171194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016136556,0.00043512436,0.00094810897,0.00011904053,0.000067442685,0.000043334854,0.00040414892,0.00039438868,0.000082445324],"category_scores_gemma":[0.000008186441,0.00032808614,0.00064958964,0.00013436803,0.00011873408,0.0000061219566,0.00002844532,0.00009133479,0.000015149514],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005705294,0.00023576398,9.625696e-7,0.0013487857,0.0011088564,1.7054728e-7,0.00003569581,0.000025327352,0.117216945,0.00012065155,0.00021320784,0.8791231],"study_design_scores_gemma":[0.0012424808,0.004723688,7.5459616e-7,0.0007353289,0.00013115123,0.0000033351394,0.000036824884,0.000013051227,0.0075802053,0.000041995074,0.98517525,0.00031594987],"about_ca_topic_score_codex":0.00046239447,"about_ca_topic_score_gemma":0.0002964318,"teacher_disagreement_score":0.98496205,"about_ca_system_score_codex":0.00036103162,"about_ca_system_score_gemma":0.0022429565,"threshold_uncertainty_score":0.9999171},"labels":[],"label_agreement":null},{"id":"W2162451701","doi":"10.2217/imt.14.7","title":"Alemtuzumab for the Treatment of Relapsing–Remitting Multiple Sclerosis","year":2014,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Alemtuzumab; Relapsing remitting; Multiple sclerosis; Medicine; Fingolimod; Oncology; Internal medicine; Immunology","score_opus":0.20229048024819685,"score_gpt":0.4048349850202537,"score_spread":0.20254450477205688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162451701","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005149272,0.9935478,0.00053050224,0.00015299235,0.00035580772,0.0050636614,0.000110888664,0.000060708207,0.00012616388],"genre_scores_gemma":[0.000100187295,0.99431056,0.001684541,0.000046293466,0.00054235646,0.0019988215,0.000078645346,0.00016361957,0.0010749584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738574,0.0001799426,0.0010004166,0.00048161272,0.0004299868,0.00052230875],"domain_scores_gemma":[0.9931188,0.0047500203,0.000611446,0.0012158859,0.00023231508,0.00007149759],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061048317,0.0005698335,0.0028523214,0.0001852106,0.00031724505,0.00003577683,0.00034910714,0.0002654574,0.000051105802],"category_scores_gemma":[0.00048512305,0.0002969566,0.0018352641,0.00026924734,0.00027731803,0.000029890733,0.000036631573,0.00023427355,0.00002587335],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001809581,0.00030674457,0.0000295662,0.005078903,0.0023641817,4.348669e-7,0.00040461277,7.921209e-7,0.00014180291,0.00001432344,0.00054996955,0.9909277],"study_design_scores_gemma":[0.003823374,0.0013108262,0.00017321396,0.014163412,0.00083045126,0.000007098681,0.00004613727,0.000147319,0.00007632717,0.0000027069182,0.97919136,0.00022778925],"about_ca_topic_score_codex":0.00016288644,"about_ca_topic_score_gemma":0.000015125967,"teacher_disagreement_score":0.99069995,"about_ca_system_score_codex":0.0004836104,"about_ca_system_score_gemma":0.0002564972,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W2513976653","doi":"10.2217/imt-2016-0070","title":"Controlling Inflammation: A Superior Way to Control TB","year":2016,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Tuberculosis; Medicine; Human immunodeficiency virus (HIV); MEDLINE; Mycobacterium tuberculosis; Family medicine; Library science; Internal medicine; Pathology; Computer science; Biology","score_opus":0.011924646046051014,"score_gpt":0.3318239860897753,"score_spread":0.3198993400437243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513976653","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064705038,0.008184866,0.0033936708,0.03859255,0.93760544,0.003091483,0.00047570164,0.000296085,0.0018897044],"genre_scores_gemma":[0.0045337845,0.0037053714,0.0002841507,0.0027155804,0.9819423,0.0005634277,0.00018831716,0.00014860218,0.005918449],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671954,0.0003115869,0.0007814817,0.000565428,0.0007871943,0.00083476625],"domain_scores_gemma":[0.99558616,0.002480675,0.00016789086,0.0008307903,0.00060232496,0.00033213283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012284413,0.00044414573,0.0014892846,0.0003078648,0.00012455414,0.000058599864,0.00034638002,0.0010420918,0.0008127377],"category_scores_gemma":[0.0033551867,0.00029421045,0.00041228987,0.00013924534,0.000108933375,0.00008813772,0.00003209005,0.0008641113,0.0013539161],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056001632,0.000036399855,0.0000940338,0.00005610822,0.0008181761,0.000047374462,0.0001354906,0.000002555161,0.045965247,0.00008278186,0.9051831,0.04197859],"study_design_scores_gemma":[0.011400321,0.0010193603,0.00028020513,0.0003822812,0.000057351685,0.00001056875,0.000008882081,0.000047013255,0.0004217458,0.00007323107,0.9859971,0.0003019343],"about_ca_topic_score_codex":0.00021922612,"about_ca_topic_score_gemma":0.00003308992,"teacher_disagreement_score":0.08081403,"about_ca_system_score_codex":0.0003389901,"about_ca_system_score_gemma":0.00046777807,"threshold_uncertainty_score":0.999951},"labels":[],"label_agreement":null},{"id":"W2550798570","doi":"10.2217/imt-2016-0079","title":"Double-Blind, Placebo-Controlled, 1:1 Randomized Phase III Clinical Trial Of Immunoxel Honey Lozenges as an Adjunct Immunotherapy in 269 Patients with Pulmonary Tuberculosis","year":2016,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Bee Products Chemical Analysis","field":"Agricultural and Biological Sciences","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Adjunct; Medicine; Placebo; Double blind; Lozenge; Clinical trial; Immunotherapy; Tuberculosis; Randomized controlled trial; Phases of clinical research; Pulmonary tuberculosis; Internal medicine; Pathology; Cancer","score_opus":0.02854180778147574,"score_gpt":0.30122457999191543,"score_spread":0.2726827722104397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2550798570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235666,0.0014677878,0.000017429073,0.0018081386,0.00027981604,0.0036932202,0.000037382404,0.0000751081,0.000264433],"genre_scores_gemma":[0.99524164,0.0030057842,0.00009406769,0.000277285,0.00032799426,0.0005150501,0.00011127395,0.000013611387,0.00041327943],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946367,0.0010840988,0.0020256462,0.0009395482,0.0007088406,0.0006051427],"domain_scores_gemma":[0.99635965,0.0017522501,0.0008941099,0.0005004489,0.00034149195,0.0001520332],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027758053,0.0005642371,0.0023905763,0.000101851576,0.00014409496,0.00007355817,0.0008839444,0.00036726767,0.0011323281],"category_scores_gemma":[0.0001884144,0.00017433475,0.0009236797,0.0007390259,0.00062199554,0.0005200091,0.0000647355,0.00033072883,0.00003872916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6691479,0.0039191814,0.0008714134,0.000002598545,0.00068968796,0.0000027541632,0.000070873975,6.852797e-7,0.1787024,0.00007016732,0.0000089308505,0.14651343],"study_design_scores_gemma":[0.97966146,0.0031969026,0.0011861958,0.00008115491,0.0001295464,0.0000023662801,0.000057842924,0.000025389545,0.01378426,0.00049743685,0.0008597568,0.0005177042],"about_ca_topic_score_codex":0.0013051855,"about_ca_topic_score_gemma":0.00015328682,"teacher_disagreement_score":0.31051356,"about_ca_system_score_codex":0.00007299236,"about_ca_system_score_gemma":0.00005259982,"threshold_uncertainty_score":0.9997808},"labels":[],"label_agreement":null},{"id":"W2792760898","doi":"10.2217/imt-2017-0162","title":"CD19-specific Chimeric Antigen Receptor-Modified (CAR)-T cell Therapy for the Treatment of Chronic Lymphocytic Leukemia in the Ibrutinib Era","year":2018,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Medicine; Chimeric antigen receptor; Leukemia; Oncology; Cancer; Immunology; Internal medicine; Immunotherapy","score_opus":0.026547901132691322,"score_gpt":0.3216215715794757,"score_spread":0.29507367044678434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792760898","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1555645,0.28863475,0.00032521458,0.0005504345,0.53279096,0.01929051,0.0006705196,0.00022959361,0.0019435198],"genre_scores_gemma":[0.031787146,0.46946228,0.00025118364,0.00023243317,0.4902411,0.0024897142,0.0010057503,0.00047252912,0.0040578367],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937703,0.0004554855,0.0013659063,0.0011559905,0.0019164061,0.0013359289],"domain_scores_gemma":[0.98994476,0.005415531,0.00072070124,0.003294325,0.00051125453,0.0001134283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015412392,0.0010809173,0.0017320456,0.00037847742,0.00037752464,0.00012149192,0.0017863269,0.0012176345,0.0005209462],"category_scores_gemma":[0.00010630672,0.0005866179,0.0010521302,0.0008790525,0.0008367351,0.000089779416,0.0000517738,0.00082507735,0.0001308223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013170376,0.00081642787,0.000008058807,0.00033432772,0.0014496165,0.000030711908,0.0066948254,0.00016094565,0.009689714,0.000037386963,0.9114397,0.05616789],"study_design_scores_gemma":[0.07028996,0.007856034,0.000049612285,0.00029639516,0.00009486583,0.00001547377,0.0003855546,0.00261695,0.008015098,0.000044210305,0.90983045,0.00050541124],"about_ca_topic_score_codex":0.0044601276,"about_ca_topic_score_gemma":0.000114104136,"teacher_disagreement_score":0.18082753,"about_ca_system_score_codex":0.07932212,"about_ca_system_score_gemma":0.06380812,"threshold_uncertainty_score":0.9996585},"labels":[],"label_agreement":null},{"id":"W2804640215","doi":"10.2217/imt-2018-0003","title":"Ragweed Sublingual Tablet Immunotherapy: Part II – Practical Considerations and Pertinent Issues","year":2018,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ragweed; Sublingual immunotherapy; Medicine; Slit; Allergy; Clinical trial; Dermatology; Immunotherapy; Allergic asthma; Asthma; Allergen immunotherapy; Intensive care medicine; Allergen; Immunology; Internal medicine; Immune system","score_opus":0.08254104935116863,"score_gpt":0.3923671133085607,"score_spread":0.3098260639573921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804640215","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038493046,0.9931958,0.00007731376,0.003162093,0.0006395617,0.0013708245,0.00003749403,0.00014748788,0.0009845042],"genre_scores_gemma":[0.000044294964,0.98872596,0.0020110356,0.0014204222,0.0016945944,0.00009492167,0.0004378693,0.00016191055,0.00540897],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972145,0.00029218284,0.001066457,0.0006094817,0.00040154633,0.0004158536],"domain_scores_gemma":[0.9980223,0.000318889,0.00048345208,0.0006989953,0.00034965554,0.00012668493],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052847905,0.00060217484,0.0019184322,0.00021393955,0.00053532707,0.00019449019,0.00006632976,0.00051114423,0.0016094429],"category_scores_gemma":[0.00026840015,0.00045855273,0.0003808125,0.00021225972,0.0003016759,0.00016254578,0.00005288335,0.0005171556,0.00009934095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005128244,0.0010494404,0.000009125016,0.0030818316,0.003937453,0.00053751975,0.0042589586,5.015421e-7,0.00018554923,0.0066551846,0.100960605,0.878811],"study_design_scores_gemma":[0.001534949,0.00062430603,0.000008561873,0.00375035,0.00032471406,0.002391458,0.000059031827,0.000041770276,0.0000124436665,0.0001479851,0.9906632,0.00044126986],"about_ca_topic_score_codex":0.00007799111,"about_ca_topic_score_gemma":0.000007068981,"teacher_disagreement_score":0.88970256,"about_ca_system_score_codex":0.00010962007,"about_ca_system_score_gemma":0.00074397173,"threshold_uncertainty_score":0.9997866},"labels":[],"label_agreement":null},{"id":"W2908942081","doi":"10.2217/imt-2018-0167","title":"Immune Checkpoint Inhibitors and Non-Small-Cell Lung Cancer Management: 2018 Update","year":2019,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Pembrolizumab; Atezolizumab; Nivolumab; Medicine; Lung cancer; Oncology; Internal medicine; Docetaxel; Avelumab; Ipilimumab; Cancer; Immunotherapy","score_opus":0.005902408804642505,"score_gpt":0.2602707838035951,"score_spread":0.2543683749989526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908942081","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022737194,0.16446915,0.00008492187,0.00078513206,0.804007,0.0032126124,0.000293508,0.0001949664,0.0042155036],"genre_scores_gemma":[0.0025026167,0.4100301,0.0007919825,0.0012449007,0.5193053,0.0006859327,0.0010542268,0.0006822309,0.0637027],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600554,0.000074775475,0.0011577191,0.0010802223,0.00086980464,0.0008119533],"domain_scores_gemma":[0.9974046,0.00014436782,0.00071116496,0.0013952185,0.00020760896,0.00013704717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006821001,0.0009723294,0.001360811,0.00042014592,0.00019475994,0.00018618362,0.00048983155,0.0011990654,0.0007070253],"category_scores_gemma":[0.000012227676,0.00085362763,0.0006422207,0.0003760897,0.00023024391,0.0001532724,0.00016987398,0.0012082722,0.00011627466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057201576,0.00025367658,0.00026916314,0.002330377,0.003031428,0.0000642323,0.000523633,0.0000013226932,0.03329525,0.000004446834,0.92914903,0.025357276],"study_design_scores_gemma":[0.01499165,0.00042321545,0.0009466347,0.0021894933,0.0005421899,0.000009025604,0.00010063827,0.000044962002,0.006820779,0.000009516677,0.97299147,0.0009304444],"about_ca_topic_score_codex":0.0015719784,"about_ca_topic_score_gemma":0.00003646023,"teacher_disagreement_score":0.2847017,"about_ca_system_score_codex":0.00068372994,"about_ca_system_score_gemma":0.0005788921,"threshold_uncertainty_score":0.99939144},"labels":[],"label_agreement":null},{"id":"W2921861485","doi":"10.2217/imt-2018-0186","title":"Toxicity Patterns Associated with Chemotherapy/Immune Checkpoint Inhibitor Combinations: A Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Meta-analysis; Chemotherapy; Toxicity; Medicine; Immune checkpoint; Immune system; Immunotherapy; Oncology; Immunology; Internal medicine","score_opus":0.0886360825971064,"score_gpt":0.34861315145748456,"score_spread":0.2599770688603782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921861485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033008322,0.99391454,0.00030590265,0.00047666524,0.0002582156,0.003654605,0.00045314385,0.0002513571,0.00035549825],"genre_scores_gemma":[0.0006223688,0.987569,0.00014343724,0.001055551,0.00011111742,0.00081971596,0.0015071175,0.00032542314,0.00784627],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.994528,0.0005128727,0.0020566604,0.0011470481,0.0010136185,0.000741796],"domain_scores_gemma":[0.9950418,0.00043276892,0.0018760994,0.0021624325,0.0003539515,0.00013298815],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012242859,0.001404346,0.009573022,0.0010581631,0.00019391521,0.00018606542,0.0006184266,0.00086736225,0.0032973746],"category_scores_gemma":[0.000044695233,0.0008994311,0.010873345,0.0027452216,0.00021120673,0.00017500957,0.00005310263,0.0009871207,0.000105536004],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007373414,0.0015423222,0.000037342892,0.0029947034,0.7517525,0.000030905998,0.00024214842,0.0000010358997,0.00009555613,0.000025774278,0.00013654055,0.2424038],"study_design_scores_gemma":[0.005719923,0.0010163783,0.00033599304,0.0026828882,0.3552176,0.00006120575,0.000032219854,0.000011912195,0.000133765,0.0000069131856,0.6337318,0.0010493891],"about_ca_topic_score_codex":0.0002761249,"about_ca_topic_score_gemma":0.00008178262,"teacher_disagreement_score":0.6335953,"about_ca_system_score_codex":0.00089178927,"about_ca_system_score_gemma":0.00075792655,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W2978287760","doi":"10.2217/imt-2018-0035","title":"Atezolizumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient with Urothelial Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Sarcoidosis and Beryllium Toxicity Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Atezolizumab; Medicine; Sarcoidosis; Malignancy; Mediastinal lymph node; Lymph node; Lymph node biopsy; Biopsy; Mediastinal lymphadenopathy; Pathology; Carcinoma; Radiology; Immunotherapy; Cancer; Internal medicine; Nivolumab; Metastasis","score_opus":0.0186478648614335,"score_gpt":0.27772663420479604,"score_spread":0.25907876934336255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978287760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454236,0.0003492622,0.000020986958,0.00039356868,0.00018119041,0.0007822252,0.0000051560864,0.00006573438,0.003659517],"genre_scores_gemma":[0.99809426,0.000101610654,0.00023338626,0.0007339163,0.00021966288,0.000082482344,0.000010424497,0.00006694685,0.00045731684],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815154,0.00009634314,0.00033015455,0.00038817246,0.0005323294,0.0005014388],"domain_scores_gemma":[0.999042,0.00004223422,0.000090843016,0.0005406284,0.00017406835,0.000110222376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019152269,0.00023632719,0.00035245696,0.00028183407,0.00012094495,0.000039148672,0.0001346428,0.00013980635,0.00016710843],"category_scores_gemma":[0.000010198645,0.00017436499,0.00009880005,0.0004545731,0.00013922201,0.000108306,0.000024586534,0.0003224259,0.0001828587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005729513,0.0007141907,0.015993953,0.000030662843,0.000033600772,0.0001926499,0.0018958196,2.3457373e-7,0.93823624,0.000016366257,0.00015793424,0.036998864],"study_design_scores_gemma":[0.014396893,0.009503887,0.19967578,0.00016377466,0.000026877206,0.000618884,0.00053546036,0.00020661256,0.7606822,0.00004151091,0.0136995455,0.00044852463],"about_ca_topic_score_codex":0.002339463,"about_ca_topic_score_gemma":0.000275065,"teacher_disagreement_score":0.18368183,"about_ca_system_score_codex":0.00021122281,"about_ca_system_score_gemma":0.00021467793,"threshold_uncertainty_score":0.71103984},"labels":[],"label_agreement":null},{"id":"W3041847701","doi":"10.2217/imt-2020-0153","title":"How COVID-19 Affects Patients Receivingc anticytokine and JAK Inhibitors in Rheumatology and Dermatology","year":2020,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Rheumatology; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Dermatology; Internal medicine; Immunology; Virology","score_opus":0.017185335524739165,"score_gpt":0.280928578010123,"score_spread":0.26374324248538383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041847701","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2633296,0.010608987,0.000025512769,0.72448003,0.00021807759,0.0011157647,0.000015644453,0.00008522697,0.00012113391],"genre_scores_gemma":[0.30240327,0.025760798,0.00014438065,0.66910887,0.00024308897,0.00020938863,0.000587078,0.0002762277,0.0012668907],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975219,0.0003717399,0.00047977062,0.0006548605,0.00035015788,0.000621593],"domain_scores_gemma":[0.9987232,0.00038360644,0.00025090558,0.0004274788,0.00006530145,0.0001494868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015224672,0.0004719292,0.0013471954,0.0005254328,0.00013246376,0.00009049916,0.00018467255,0.0009417241,0.000054376942],"category_scores_gemma":[0.0005529682,0.0004235854,0.000099377474,0.0002809383,0.0005371428,0.00013728779,0.00013394588,0.0019053812,0.000013964757],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063628616,0.00011108166,0.26438776,0.00326174,0.00030636322,0.0023642322,0.0016909852,9.9383854e-8,0.0012830162,0.000030916734,0.7121548,0.013772721],"study_design_scores_gemma":[0.007937842,0.00046452752,0.0122201545,0.00034331644,0.0000254547,0.00058601814,0.00010684472,0.000039070448,0.00018536988,0.000116033705,0.97756004,0.00041529522],"about_ca_topic_score_codex":0.00015626373,"about_ca_topic_score_gemma":0.000013424973,"teacher_disagreement_score":0.2654053,"about_ca_system_score_codex":0.00011885685,"about_ca_system_score_gemma":0.00038224895,"threshold_uncertainty_score":0.9998216},"labels":[],"label_agreement":null},{"id":"W3047233339","doi":"10.2217/imt-2020-0158","title":"Romosozumab in the Treatment of Osteoporosis","year":2020,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University","funders":"Amgen","keywords":"Sclerostin; Osteoporosis; Medicine; Bone resorption; Bone mineral; Bone Density Conservation Agents; Wnt signaling pathway; Internal medicine; Bioinformatics; Chemistry; Signal transduction; Biology; Biochemistry","score_opus":0.0488655667525898,"score_gpt":0.34608488723398706,"score_spread":0.29721932048139726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047233339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97231096,0.005388051,0.0000057339216,0.020036126,0.000028228427,0.0006621868,0.0000057071356,0.000015211384,0.0015477955],"genre_scores_gemma":[0.99116737,0.0045400467,0.00018749668,0.0038441878,0.000066505345,0.000060659477,0.000009338882,0.0000137391135,0.0001106886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991254,0.00006980522,0.00024233099,0.00012672466,0.00023993869,0.00019580497],"domain_scores_gemma":[0.99952644,0.00008113132,0.000041302934,0.0002528593,0.000033274744,0.00006501161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011969315,0.00008623531,0.00024647854,0.000039880728,0.00003059402,0.000007217426,0.00009352212,0.00004802418,0.00017680821],"category_scores_gemma":[0.000015829,0.000049299557,0.0000908821,0.00028156664,0.00005001406,0.000023018583,0.0000034113634,0.000090441885,0.000035841575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066119917,0.0033010328,0.07043677,0.00024898577,0.00014971949,0.00011796663,0.07621484,0.0000049675205,0.12198655,0.0005209657,0.0015304514,0.71887577],"study_design_scores_gemma":[0.025468308,0.027159138,0.43743426,0.00010517106,0.000038950795,0.000056820933,0.004312865,0.0004188456,0.04773647,0.00013192542,0.4568847,0.00025251947],"about_ca_topic_score_codex":0.00037171252,"about_ca_topic_score_gemma":0.00002423002,"teacher_disagreement_score":0.7186232,"about_ca_system_score_codex":0.000052301246,"about_ca_system_score_gemma":0.0001169287,"threshold_uncertainty_score":0.20103775},"labels":[],"label_agreement":null},{"id":"W3109227879","doi":"10.2217/imt-2020-0265","title":"Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Eosinophilia; Medicine; Eosinophil; Melanoma; Immunotherapy; Internal medicine; Immunology; Retrospective cohort study; Gastroenterology; Oncology; Cancer research; Cancer; Asthma","score_opus":0.006064718479399405,"score_gpt":0.21165744942955636,"score_spread":0.20559273095015695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109227879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957527,0.0017302411,0.000033555487,0.00032015028,0.00040462523,0.0006276846,0.000009988614,0.00007698296,0.0010440502],"genre_scores_gemma":[0.9985976,0.000107979235,0.00010078799,0.00085427635,0.000015453259,0.000030472242,0.000064723514,0.0000452926,0.00018342263],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99872804,0.00014279663,0.00044915857,0.0003156194,0.000070282455,0.0002940799],"domain_scores_gemma":[0.9991763,0.00013605146,0.0002641638,0.00030834225,0.000098885095,0.000016225671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008587703,0.00024135994,0.00035812054,0.00011450134,0.00008612004,0.000013505771,0.00022767493,0.00014425194,0.0007208198],"category_scores_gemma":[0.000044292858,0.00019612329,0.00008762709,0.00025274427,0.00009375824,0.00015091662,0.000017912525,0.00035203356,0.00022374291],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010666021,0.0012706377,0.07274279,0.000013434921,0.00028636673,8.324822e-7,0.002462036,0.00009750787,0.72870135,0.00039678274,0.00009327097,0.18326896],"study_design_scores_gemma":[0.014828459,0.0052892575,0.668733,0.00014413541,0.000008717061,0.000002293834,0.00033548113,0.000017680528,0.28544298,0.000016580894,0.024845887,0.00033554676],"about_ca_topic_score_codex":0.000020737974,"about_ca_topic_score_gemma":0.0000014331548,"teacher_disagreement_score":0.5959902,"about_ca_system_score_codex":0.000045260484,"about_ca_system_score_gemma":0.00003441874,"threshold_uncertainty_score":0.79976755},"labels":[],"label_agreement":null},{"id":"W3199359059","doi":"10.2217/imt-2021-0133","title":"Immunoregulatory T cell Epitope Peptides for the Treatment of Allergic Disease","year":2021,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Regeneron Pharmaceuticals","keywords":"Epitope; Immunology; Disease; Medicine; Immunotherapy; Epitope mapping; Antibody; Immune system; Pathology","score_opus":0.04693637287601039,"score_gpt":0.33266512176056745,"score_spread":0.28572874888455707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199359059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014655924,0.99678177,0.00019305648,0.00010067486,0.00039670267,0.0021348791,0.000081363,0.000025781517,0.00013922184],"genre_scores_gemma":[0.00008915649,0.9936834,0.00023781187,0.00008990717,0.00034831103,0.00034800905,0.0006207417,0.00010811889,0.0044745193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998513,0.000102210324,0.000645321,0.00031379526,0.00021235451,0.0002133443],"domain_scores_gemma":[0.99812144,0.0003913705,0.0003770499,0.00087813934,0.00016583937,0.00006617641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011173562,0.00039764596,0.0016093344,0.00007607191,0.00012305082,0.000026009802,0.00013719713,0.00016473436,0.0001470282],"category_scores_gemma":[0.000013128969,0.00022352878,0.0014532218,0.00014013503,0.0001052325,0.00002555048,0.000010107829,0.00008928386,0.000011367851],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013082319,0.00048158568,0.0000020941586,0.0022322237,0.0011125588,0.00002662153,0.0003050175,0.000004468895,0.000022412689,0.00026131785,0.00047590001,0.994945],"study_design_scores_gemma":[0.0014724274,0.00045883938,0.000046584402,0.0034385421,0.0010817061,0.000022513255,0.000059005,0.000046133926,0.000021470145,0.000014782145,0.99314123,0.00019677806],"about_ca_topic_score_codex":0.000023674647,"about_ca_topic_score_gemma":0.0000017363068,"teacher_disagreement_score":0.9947482,"about_ca_system_score_codex":0.0001569389,"about_ca_system_score_gemma":0.00057211955,"threshold_uncertainty_score":0.91152394},"labels":[],"label_agreement":null},{"id":"W3210787730","doi":"10.2217/imt-2021-0068","title":"Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System","year":2021,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Adverse effect; Adverse Event Reporting System; Common Terminology Criteria for Adverse Events; Internal medicine; Ipilimumab; Oncology; Cancer; Immunotherapy; Nivolumab; Etiology; MedDRA; Kidney cancer; Pharmacovigilance","score_opus":0.010245077100603362,"score_gpt":0.2668065637972968,"score_spread":0.25656148669669343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210787730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944671,0.0028671299,0.00015029007,0.0008315501,0.00093046785,0.00054010085,0.000028052897,0.00005869372,0.00012660603],"genre_scores_gemma":[0.997578,0.0003627406,0.0002584687,0.00034076232,0.0002847028,0.00003160108,0.00007699194,0.00004119635,0.0010255404],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99679273,0.00039183602,0.0017016942,0.00035631208,0.00044898834,0.00030844848],"domain_scores_gemma":[0.996523,0.00014891892,0.0024627163,0.0005276486,0.0002839127,0.000053804957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021994067,0.00024138564,0.0006670259,0.00008674728,0.00022673498,0.000010100975,0.00010918596,0.00018517596,0.000085408],"category_scores_gemma":[0.0002417615,0.00018297143,0.0003753924,0.0002965616,0.000099564306,0.00010137167,0.000056166868,0.00035994683,0.000011170867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003048438,0.00016516134,0.31128067,0.00023183585,0.0024293845,0.00015081433,0.0016606027,0.000055730652,0.67631704,0.000036278194,0.00009578478,0.0045282827],"study_design_scores_gemma":[0.0077857315,0.00044517757,0.91735643,0.0007464971,0.00039380923,0.0004658354,0.0019182877,0.00018378318,0.06729725,0.000025366364,0.0031020269,0.00027977934],"about_ca_topic_score_codex":0.000647896,"about_ca_topic_score_gemma":0.000034840366,"teacher_disagreement_score":0.60901976,"about_ca_system_score_codex":0.00040895186,"about_ca_system_score_gemma":0.00028537324,"threshold_uncertainty_score":0.74613583},"labels":[],"label_agreement":null},{"id":"W4282831736","doi":"10.2217/imt-2021-0250","title":"No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors","year":2022,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Immune system; Immune checkpoint; Immunotherapy; Retrospective cohort study; Cancer; Population; Immunology","score_opus":0.037653132573444666,"score_gpt":0.35211722116296235,"score_spread":0.3144640885895177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282831736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990419,0.0023801613,0.00014556546,0.0030859895,0.0015635611,0.0017713837,0.00015987169,0.00015217908,0.00032229075],"genre_scores_gemma":[0.966998,0.0025029068,0.0016769689,0.0039089266,0.00086737674,0.0007689402,0.00020703363,0.00015108209,0.02291881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971675,0.00022025182,0.0012343636,0.00044349933,0.0004875391,0.0004468135],"domain_scores_gemma":[0.99783486,0.00086388993,0.0005763704,0.00049127446,0.00015176144,0.000081825296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028030649,0.00029929256,0.0008560474,0.00013572512,0.0005120058,0.000057129328,0.00020711271,0.00019537653,0.0006946473],"category_scores_gemma":[0.00031277467,0.00023830826,0.0007026693,0.00026299042,0.000111366426,0.00011799006,0.000098454,0.000509004,0.000015064527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024827214,0.0009136664,0.7610055,0.0000993918,0.004612154,0.000010854364,0.0006951974,0.0000010435467,0.09096732,0.000050586914,0.0041024727,0.11271457],"study_design_scores_gemma":[0.017032968,0.002872381,0.6098418,0.000039584666,0.0001447084,0.000019401537,0.00019967499,0.000033915683,0.003813365,0.00007625421,0.36556858,0.00035730857],"about_ca_topic_score_codex":0.00032568048,"about_ca_topic_score_gemma":0.000009765259,"teacher_disagreement_score":0.3614661,"about_ca_system_score_codex":0.00062132784,"about_ca_system_score_gemma":0.00025503428,"threshold_uncertainty_score":0.9717929},"labels":[],"label_agreement":null},{"id":"W4322617905","doi":"10.2217/imt-2022-0210","title":"Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Aplastic anemia; Medicine; Pembrolizumab; Anemia; Immunology; Globulin; Immunotherapy; Internal medicine; Immune system; Gastroenterology; Bone marrow","score_opus":0.03739182895557941,"score_gpt":0.37282529568210915,"score_spread":0.33543346672652974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322617905","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006409674,0.99335873,0.000081884486,0.00022534783,0.0005524901,0.0047482094,0.00073434884,0.00010003487,0.00013487601],"genre_scores_gemma":[0.0000018029775,0.9935279,0.0007762878,0.0011384011,0.00029349967,0.0005868529,0.0006053332,0.00019862922,0.0028713106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968284,0.000103867445,0.0016528448,0.00072843855,0.00028800408,0.0003984905],"domain_scores_gemma":[0.9974239,0.00037285037,0.00076236174,0.0010264745,0.00026826476,0.00014615353],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000859635,0.00065416034,0.0031583505,0.0003895793,0.00009566807,0.00005136182,0.00020000238,0.00044519413,0.00014029977],"category_scores_gemma":[0.0002170182,0.00048945745,0.0010617308,0.0010282695,0.000112062386,0.000067481014,0.000051448682,0.0004516676,0.000016369753],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009995212,0.00004530466,5.927865e-7,0.30291677,0.0008893071,0.012431139,0.000098071185,1.1252134e-8,0.000032999586,0.000015760108,0.0064070984,0.67616343],"study_design_scores_gemma":[0.0014899449,0.0005292821,0.000004597139,0.24529323,0.00068302895,0.104962595,0.0000064673054,5.061201e-7,0.0000067994915,0.000006728309,0.64671975,0.00029705957],"about_ca_topic_score_codex":0.00006682931,"about_ca_topic_score_gemma":0.000010841343,"teacher_disagreement_score":0.67586637,"about_ca_system_score_codex":0.00019171489,"about_ca_system_score_gemma":0.0009992389,"threshold_uncertainty_score":0.9997557},"labels":[],"label_agreement":null},{"id":"W4375855360","doi":"10.2217/imt-2023-0062","title":"Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Bristol-Myers Squibb","keywords":"Psoriasis; Plaque psoriasis; Medicine; Dermatology","score_opus":0.01778521998774822,"score_gpt":0.26715033747022876,"score_spread":0.24936511748248053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375855360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920935,0.0053975517,0.000012106691,0.000118494645,0.000412332,0.00083134166,0.00021411532,0.00026340934,0.0006571356],"genre_scores_gemma":[0.98824066,0.0017315914,0.00012489638,0.00003354687,0.000060197402,0.0003176058,0.00040258485,0.00006253612,0.0090264045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845594,0.00028123174,0.00035538356,0.0003934523,0.000074870935,0.0004391473],"domain_scores_gemma":[0.9989144,0.00025977707,0.00016033293,0.00059748575,0.00004496247,0.00002301295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015790449,0.00035744946,0.0005639017,0.00024967862,0.0001781051,0.000014647292,0.00022594674,0.00018542631,0.0003521155],"category_scores_gemma":[0.0000071274553,0.00025078896,0.00017756253,0.0004573494,0.00012527952,0.00007034725,0.000021452937,0.00007826335,0.0005316535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009170914,0.004034135,0.059411567,0.000028595345,0.0071291737,0.00041713292,0.036844198,0.000014822195,0.470347,0.00035211042,0.0013869388,0.41086343],"study_design_scores_gemma":[0.07113162,0.021589007,0.17758341,0.00015074993,0.00083083863,0.00024559553,0.025809253,0.000008495618,0.60064846,0.00010019133,0.100452036,0.0014503209],"about_ca_topic_score_codex":0.0006552352,"about_ca_topic_score_gemma":0.0002115085,"teacher_disagreement_score":0.4094131,"about_ca_system_score_codex":0.00007470354,"about_ca_system_score_gemma":0.00007849951,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4376640915","doi":"10.2217/imt-2022-0139","title":"Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Circadian rhythm; Medicine; Melanoma; Immune system; Immune checkpoint; Association (psychology); Oncology; Internal medicine; Immunotherapy; Immunology; Cancer research; Psychology","score_opus":0.017196116946273547,"score_gpt":0.3009920710369966,"score_spread":0.28379595409072306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376640915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997315,0.00070768443,0.000014680735,0.0004583708,0.00022830017,0.00039226428,0.000024938296,0.00003014426,0.00082864746],"genre_scores_gemma":[0.9984029,0.0009231979,0.00025123617,0.00003285469,0.00003473656,0.000021345013,0.000036675843,0.00003256162,0.00026449273],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99831164,0.00007236546,0.0008573108,0.00015705072,0.0003744781,0.00022716202],"domain_scores_gemma":[0.9987602,0.000170405,0.00059284386,0.0002913367,0.0001582739,0.000026909924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007534877,0.00014490975,0.0005516661,0.00039307325,0.000027589607,0.0000034699347,0.000105144296,0.00012976542,0.00013184808],"category_scores_gemma":[0.00007309035,0.00012497552,0.00018804435,0.0010083992,0.00010625372,0.00008368855,0.000018578956,0.00015151342,0.0000024890064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049247383,0.00018764955,0.06987806,0.000107656466,0.0003673227,0.0000066012276,0.0028577067,0.00003433167,0.8967872,0.000029343186,0.000023014163,0.024796365],"study_design_scores_gemma":[0.009202248,0.0010404584,0.60344607,0.0006757471,0.000030300358,0.0000040061027,0.0010313039,0.00007983029,0.38360247,0.000025823942,0.00072428555,0.00013745036],"about_ca_topic_score_codex":0.0011824284,"about_ca_topic_score_gemma":0.00023848243,"teacher_disagreement_score":0.533568,"about_ca_system_score_codex":0.00015087936,"about_ca_system_score_gemma":0.00020888737,"threshold_uncertainty_score":0.5096353},"labels":[],"label_agreement":null},{"id":"W4383186917","doi":"10.2217/imt-2023-0069","title":"A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Pfizer","keywords":"Alopecia areata; Medicine; Dermatology; Pediatrics","score_opus":0.012510771235180951,"score_gpt":0.2805351663317076,"score_spread":0.26802439509652665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383186917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960495,0.0010439685,0.000044468874,0.00057925977,0.000043265598,0.0008623943,0.00007021109,0.0001234311,0.0011834672],"genre_scores_gemma":[0.99567133,0.00082088937,0.00013898169,0.0010171658,0.00008636085,0.00014448036,0.00018635677,0.000042806194,0.0018916097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99934644,0.000013117381,0.00009980284,0.00020749251,0.000109126464,0.00022399877],"domain_scores_gemma":[0.9996374,0.000038553106,0.000022669567,0.00021348694,0.000019450486,0.00006840134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004893376,0.00014273149,0.00018902084,0.00009316477,0.00006184077,0.000013734629,0.000039029637,0.000048028953,0.000019367742],"category_scores_gemma":[0.000012198098,0.00009679556,0.000049035854,0.00012589985,0.000034984543,0.000025651327,0.000004830694,0.000044937377,0.000036591264],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04758425,0.0013299771,0.065877594,0.0004045485,0.0004892521,0.0003562075,0.015286078,0.0000047925614,0.006460037,0.0002649915,0.0076938625,0.8542484],"study_design_scores_gemma":[0.17443284,0.02489839,0.48433802,0.005689836,0.00018712769,0.00011142919,0.013348284,0.0010748308,0.011077131,0.00017106457,0.28342927,0.0012417858],"about_ca_topic_score_codex":0.00010912882,"about_ca_topic_score_gemma":0.0001113977,"teacher_disagreement_score":0.8530066,"about_ca_system_score_codex":0.000034012613,"about_ca_system_score_gemma":0.000040604857,"threshold_uncertainty_score":0.39472082},"labels":[],"label_agreement":null},{"id":"W4383872841","doi":"10.2217/imt-2022-0257","title":"An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic","year":2023,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Dosing; Lung cancer; Adverse effect; Internal medicine; Cancer; Retrospective cohort study; Toxicity; Gastroenterology; Immunotherapy","score_opus":0.03164804547800199,"score_gpt":0.40218010515864516,"score_spread":0.3705320596806432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921099,0.004655593,0.00033185305,0.0010433669,0.0002204722,0.0011481536,0.000019765856,0.00007480153,0.0003960878],"genre_scores_gemma":[0.98718554,0.009228584,0.00025750202,0.0027253286,0.000053913038,0.00031069847,0.00002909961,0.00004538123,0.00016393277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99812096,0.00020865946,0.0005651593,0.0003525857,0.00033706918,0.0004155627],"domain_scores_gemma":[0.99888885,0.0002017195,0.00018938139,0.00061763934,0.000040847568,0.000061564446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011723731,0.0002294195,0.00043104074,0.00036819198,0.000077469704,0.000026351296,0.00033844693,0.00012739773,0.00017493925],"category_scores_gemma":[0.000013964018,0.00016933861,0.00013963213,0.0011115127,0.00009807705,0.00011478879,0.0000170857,0.00033290184,0.0000016511782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039093047,0.00044426872,0.31357294,0.00022281414,0.00010032984,0.000058182442,0.007432963,0.0009770127,0.62614906,0.000031429827,0.00012393479,0.046977755],"study_design_scores_gemma":[0.025152365,0.00064652506,0.9567444,0.00032224727,0.000033472486,0.000038728478,0.002547935,0.0075548077,0.002845919,0.000081204074,0.003719788,0.0003126346],"about_ca_topic_score_codex":0.0025655502,"about_ca_topic_score_gemma":0.0010336738,"teacher_disagreement_score":0.6431714,"about_ca_system_score_codex":0.0006190879,"about_ca_system_score_gemma":0.0007984939,"threshold_uncertainty_score":0.6905428},"labels":[],"label_agreement":null},{"id":"W4384662972","doi":"10.2217/imt-2023-0012","title":"Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Ulcerative colitis; Tofacitinib; Medicine; Colitis; Drug; Inflammation; Internal medicine; Immunology; Pharmacology; Disease","score_opus":0.04020959227294852,"score_gpt":0.3431351967940178,"score_spread":0.3029256045210693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384662972","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006316854,0.99423194,0.00026408656,0.000030038453,0.00025434454,0.0033691858,0.0011339065,0.000017085224,0.00006770326],"genre_scores_gemma":[0.000022298858,0.9919767,0.00012903629,0.00008861451,0.00025426428,0.0024140582,0.00034017806,0.000111320995,0.0046635624],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988416,0.00011548718,0.00037381655,0.00033882988,0.00009179873,0.00023849882],"domain_scores_gemma":[0.998917,0.00008137722,0.00018245364,0.00066512317,0.00010731719,0.000046726767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010333723,0.00034439287,0.0006279857,0.000046321795,0.00010964066,0.000029412928,0.0002820677,0.00020053299,0.00001756505],"category_scores_gemma":[0.000016194164,0.00022128655,0.00065509544,0.00008250658,0.000052902382,0.0000014442837,0.00002314815,0.000039078463,0.000037702168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021913142,0.00010826702,2.9783826e-7,0.0013212973,0.0019290112,0.0000110215,0.0002637217,0.000051796236,0.00004330588,0.0001916855,0.0017440042,0.9921443],"study_design_scores_gemma":[0.0007929775,0.0005025813,0.000056224315,0.00047453344,0.00018650801,0.000005514928,0.000018815168,0.00001195142,0.00012964781,0.000029266694,0.99754596,0.000246008],"about_ca_topic_score_codex":0.000016801014,"about_ca_topic_score_gemma":0.00007004617,"teacher_disagreement_score":0.995802,"about_ca_system_score_codex":0.000077459816,"about_ca_system_score_gemma":0.00036044372,"threshold_uncertainty_score":0.9023804},"labels":[],"label_agreement":null},{"id":"W4386591643","doi":"10.2217/imt-2023-0039","title":"Association Between Age and Efficacy of First-Line Immunotherapy-Based Combination Therapies for Mrcc: A Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Meta-analysis; Renal cell carcinoma; Sunitinib; Hazard ratio; Internal medicine; Kidney cancer; Immunotherapy; Oncology; Cancer; Confidence interval","score_opus":0.15708852634186113,"score_gpt":0.3821562660851957,"score_spread":0.22506773974333458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386591643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011222706,0.9927563,0.0008545556,0.00044746452,0.000072667135,0.0041683856,0.00043158737,0.000120175784,0.000026570344],"genre_scores_gemma":[0.0014549167,0.9917971,0.00084499374,0.00007406967,0.000102216385,0.0011201963,0.0021843298,0.000216413,0.0022057493],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9965617,0.0003521716,0.0014582494,0.0006215803,0.000633918,0.00037238077],"domain_scores_gemma":[0.9939357,0.0031322376,0.0016618293,0.00090238557,0.00029852646,0.00006934432],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012307357,0.00073391094,0.006565322,0.0009883291,0.00013576803,0.00006731755,0.00023728002,0.00052420184,0.00011391429],"category_scores_gemma":[0.00010460149,0.0005138011,0.005555232,0.0012265814,0.00008093517,0.000056378398,0.000021582147,0.00028349794,0.000012447213],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028084728,0.00050547364,0.00033231155,0.0062386706,0.67490524,0.000013169836,0.00034933383,0.0000070660453,0.000025765907,0.00004238754,0.00007381408,0.3172259],"study_design_scores_gemma":[0.006880107,0.0015153609,0.0027412414,0.00082162383,0.5487387,0.000002363251,0.000012151319,0.00003796535,0.00008740632,0.00014676727,0.43849057,0.0005257306],"about_ca_topic_score_codex":0.00016274287,"about_ca_topic_score_gemma":0.000030538296,"teacher_disagreement_score":0.43841678,"about_ca_system_score_codex":0.0005152338,"about_ca_system_score_gemma":0.00017078956,"threshold_uncertainty_score":0.99973136},"labels":[],"label_agreement":null},{"id":"W4389951978","doi":"10.2217/imt-2023-0201","title":"Epicutaneous Immunotherapy with Viaskin Peanut in toddlers: a plain language summary","year":2023,"lang":"en","type":"letter","venue":"Immunotherapy","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Genentech; UnitedHealth Group; Thermo Fisher Scientific; Food Allergy Research and Education","keywords":"Immunotherapy; Oral immunotherapy; Medicine; Psychology; Immunology; Immune system","score_opus":0.01674315307908023,"score_gpt":0.2877756399452742,"score_spread":0.27103248686619397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389951978","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12829812,0.043665726,0.00007404653,0.8057379,0.0011039104,0.0043230657,0.0002922213,0.0013183036,0.015186712],"genre_scores_gemma":[0.013692642,0.021495689,0.0007374812,0.767473,0.005824224,0.0007012617,0.003017719,0.0013717309,0.18568626],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99580294,0.0002964956,0.0006563297,0.0008939553,0.0011281354,0.0012221255],"domain_scores_gemma":[0.99783176,0.00043711468,0.0001996251,0.0013324264,0.000106138235,0.00009291882],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004695422,0.0007755351,0.0011877791,0.0010602048,0.00012803677,0.000114738556,0.0006432968,0.001089294,0.0008455325],"category_scores_gemma":[0.000038040856,0.00060720183,0.0003855199,0.0010039667,0.00029323046,0.00010286558,0.00006013078,0.0039901547,0.0004709763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065641287,0.00044728126,0.00031145065,0.0006165438,0.0022026715,0.06701543,0.0042408644,0.000020307694,0.0106364405,0.000026540793,0.8197581,0.088160224],"study_design_scores_gemma":[0.005719182,0.0022977628,0.0010794178,0.0016325931,0.000009326793,0.00074472814,0.0004390256,0.000053764128,0.0005029453,0.000056127443,0.9866583,0.0008068437],"about_ca_topic_score_codex":0.0014937868,"about_ca_topic_score_gemma":0.00053057057,"teacher_disagreement_score":0.17049955,"about_ca_system_score_codex":0.000355968,"about_ca_system_score_gemma":0.00044151855,"threshold_uncertainty_score":0.99963796},"labels":[],"label_agreement":null},{"id":"W4391882558","doi":"10.2217/imt-2023-0293","title":"Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"","keywords":"Medicine; Rheumatoid arthritis; Crohn's disease; Internal medicine; Janus kinase; Disease; Oncology; Malignancy; Cytokine","score_opus":0.029763640887804577,"score_gpt":0.3346496295131636,"score_spread":0.30488598862535904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391882558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042582772,0.99472195,0.00027942573,0.00003702213,0.00039601352,0.0026334452,0.0014342958,0.000017761417,0.000054235767],"genre_scores_gemma":[0.0000822382,0.99267805,0.00009372706,0.00012402661,0.00043229345,0.0020888122,0.0004382454,0.00013626434,0.003926366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986992,0.0000701684,0.00041651755,0.0004468656,0.00011406676,0.0002531882],"domain_scores_gemma":[0.9987185,0.00004203773,0.00013905759,0.0009277625,0.00007325365,0.0000993664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008889708,0.0004459407,0.0005887242,0.00005811621,0.00008804561,0.000054317432,0.0003559479,0.00017715232,0.000029317756],"category_scores_gemma":[0.000016348604,0.00026045486,0.0010992727,0.00007243757,0.000065498265,0.0000017567138,0.000031384923,0.00005507145,0.000047532034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00147905,0.00019614153,0.0000015521941,0.003781246,0.0016473568,0.00005783089,0.00008466682,0.000030708175,0.0000606383,0.0002615236,0.002903548,0.98949575],"study_design_scores_gemma":[0.000519663,0.00019473082,0.00004012744,0.00076857064,0.0007952346,0.000003917374,0.0000058164733,0.00002055285,0.000028206043,0.00004696715,0.99728084,0.00029535816],"about_ca_topic_score_codex":0.0000051659285,"about_ca_topic_score_gemma":0.0000055062396,"teacher_disagreement_score":0.9943773,"about_ca_system_score_codex":0.000060751583,"about_ca_system_score_gemma":0.00053199957,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W4394873105","doi":"10.2217/imt-2023-0219","title":"Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Crohn's disease; Internal medicine; Monoclonal antibody; Monoclonal; Disease; Immunology; Antibody","score_opus":0.016375999755439376,"score_gpt":0.3122671550094165,"score_spread":0.29589115525397713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394873105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018806029,0.99598974,0.00012555839,0.000021876065,0.00016887148,0.001195166,0.0004401835,0.000012752964,0.00016527806],"genre_scores_gemma":[0.0003355423,0.99738747,0.00022400296,0.00015933363,0.00020864297,0.0006056944,0.0005237635,0.00008499978,0.00047053397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984745,0.00024429968,0.0004411016,0.0004322627,0.00016370548,0.0002441715],"domain_scores_gemma":[0.998996,0.000018075605,0.0001224826,0.00076153665,0.0000349172,0.000066972665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014535648,0.00041539708,0.0005311236,0.00011908248,0.00006187488,0.000070477494,0.00038419192,0.00017976244,0.000022877228],"category_scores_gemma":[0.000007314935,0.0002671594,0.00057679426,0.00015776255,0.000050701816,0.0000033211268,0.00003742471,0.00013263883,0.000054690154],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035642317,0.00025781486,0.0000027875894,0.0013621603,0.00048428835,0.0006719205,0.00026095472,0.0000424712,0.000027330852,0.00009885144,0.00042875257,0.99600625],"study_design_scores_gemma":[0.00066106656,0.00019966734,0.0002515085,0.0023431708,0.00043491475,0.000024267476,0.000023071514,0.000050286468,0.000014608032,0.00009316672,0.99548084,0.00042342636],"about_ca_topic_score_codex":0.000022199794,"about_ca_topic_score_gemma":0.000008247368,"teacher_disagreement_score":0.9955828,"about_ca_system_score_codex":0.000102989296,"about_ca_system_score_gemma":0.00042524913,"threshold_uncertainty_score":0.99997807},"labels":[],"label_agreement":null},{"id":"W4403247213","doi":"10.1080/1750743x.2024.2408216","title":"Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; Kingston Health Sciences Centre; University of Ottawa","funders":"","keywords":"Medicine; Immunotherapy; Allergen immunotherapy; Omalizumab; Desensitization (medicine); Allergen; Immunology; Dosing; Allergy; Intensive care medicine; Immunoglobulin E; Immune system; Internal medicine; Antibody","score_opus":0.1560110096589077,"score_gpt":0.3240526827005774,"score_spread":0.1680416730416697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403247213","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003329968,0.9894767,0.0024735816,0.0013564962,0.00089125417,0.004011978,0.0004172837,0.00011704064,0.0012223832],"genre_scores_gemma":[0.00008233951,0.98666644,0.0013664752,0.001289577,0.0013016271,0.0011731518,0.0017424298,0.0003315759,0.0060464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973033,0.00012147294,0.00089234556,0.000719263,0.00047432745,0.00048927864],"domain_scores_gemma":[0.99866366,0.00019740105,0.00024732732,0.0007580662,0.00002413801,0.000109416236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041000344,0.00072944665,0.0014757542,0.00022455904,0.00031033388,0.00012665732,0.0003552284,0.00038691296,0.00047341606],"category_scores_gemma":[0.00001052775,0.00045261643,0.0013368055,0.00023608076,0.00010637569,0.00006425243,0.00004432272,0.0004648862,0.00031676466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017091051,0.00017707045,4.045401e-7,0.0010846611,0.0029288586,0.000025044572,0.0008157498,0.00000995412,0.00006858413,0.0026314533,0.008245992,0.9838413],"study_design_scores_gemma":[0.0007784863,0.00026917973,0.000022882989,0.0025196315,0.00050492794,0.00044964565,0.00007419259,0.00022225977,0.0000033994763,0.00017079069,0.99450564,0.0004789403],"about_ca_topic_score_codex":0.000011663813,"about_ca_topic_score_gemma":0.000004465901,"teacher_disagreement_score":0.9862597,"about_ca_system_score_codex":0.00034539102,"about_ca_system_score_gemma":0.00025342117,"threshold_uncertainty_score":0.9997926},"labels":[],"label_agreement":null},{"id":"W4405111359","doi":"10.1080/1750743x.2024.2436346","title":"Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review &amp; meta-analysis","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Radiosensitizer; Oncology; Cisplatin; Head and neck squamous-cell carcinoma; Immunotherapy; Meta-analysis; Internal medicine; Radiation therapy; Standard of care; Head and neck cancer; Chemotherapy; Cancer","score_opus":0.07829244723347409,"score_gpt":0.3949451119656623,"score_spread":0.3166526647321882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405111359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016419586,0.99355125,0.000033802644,0.00017655826,0.00013908168,0.0058082207,0.00011003543,0.00006483154,0.00009981736],"genre_scores_gemma":[0.000034307617,0.9955425,0.00007223131,0.0006964257,0.000037665246,0.0022211855,0.00036143122,0.00012328145,0.0009109369],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961327,0.00040101173,0.0017982849,0.0007194679,0.000581082,0.00036750914],"domain_scores_gemma":[0.9978801,0.00024785651,0.0007256334,0.0009144489,0.00015153205,0.00008041519],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077968516,0.00086227426,0.011780603,0.0007723243,0.00006978498,0.000076532415,0.00018287306,0.00020032324,0.00018239104],"category_scores_gemma":[0.000048541508,0.0004552623,0.00220724,0.001934344,0.00007991778,0.00008422906,0.00003252609,0.00051312376,0.00008416941],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002745929,0.00014169594,0.000032928107,0.6869547,0.19265696,0.000008413959,0.00028249688,1.4322498e-7,1.42686e-7,0.00002551158,0.00035121216,0.11951837],"study_design_scores_gemma":[0.0011604202,0.0002026821,0.00002818431,0.20460911,0.38246265,0.000014266589,0.0000047147223,0.0000023693995,6.788661e-8,0.0000030730876,0.4111161,0.00039635957],"about_ca_topic_score_codex":0.00008258654,"about_ca_topic_score_gemma":0.000050474082,"teacher_disagreement_score":0.48234555,"about_ca_system_score_codex":0.00029042287,"about_ca_system_score_gemma":0.00024270502,"threshold_uncertainty_score":0.9997899},"labels":[],"label_agreement":null},{"id":"W4405200272","doi":"10.1080/1750743x.2024.2436838","title":"Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Research Canada; Dalhousie University","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; American Academy of Allergy Asthma and Immunology","keywords":"Adverse effect; Medicine; Immune system; Melanoma; Pembrolizumab; Incidence (geometry); Meta-analysis; Oncology; Ipilimumab; Internal medicine; Immunotherapy; Immunology; Cancer research","score_opus":0.03227925669359021,"score_gpt":0.35404011530669366,"score_spread":0.32176085861310344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405200272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005051981,0.9934629,0.000002289606,0.00015844146,0.0001608934,0.005872201,0.000122030244,0.000058927013,0.0001118],"genre_scores_gemma":[0.00018465504,0.99601513,0.000044648965,0.00015992184,0.000016884786,0.0009629939,0.00016927363,0.00013940308,0.002307061],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993595,0.0007127228,0.0040218155,0.00075507036,0.0005284726,0.00038691724],"domain_scores_gemma":[0.9968201,0.00019268387,0.0015001873,0.001309348,0.00009694297,0.00008077289],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0019266279,0.00097287877,0.014617138,0.0013581854,0.000039639686,0.000013376704,0.00034806508,0.00051810866,0.0005859232],"category_scores_gemma":[0.00006171026,0.000587514,0.010972455,0.0032200245,0.00016067446,0.00009688615,0.00007490842,0.0006930108,0.000055376564],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004865154,0.00011866935,0.0000017234645,0.652312,0.3415019,0.000035309447,0.00010964664,7.73574e-8,0.0000073513424,0.000015325984,0.000030254003,0.005819112],"study_design_scores_gemma":[0.0008916709,0.00020814236,0.000009894321,0.14811352,0.8225788,0.00014648552,0.000027541246,0.0000019863967,0.0000015980577,0.000010077336,0.02755729,0.00045299742],"about_ca_topic_score_codex":0.0002528082,"about_ca_topic_score_gemma":0.000021382126,"teacher_disagreement_score":0.5041985,"about_ca_system_score_codex":0.00029133074,"about_ca_system_score_gemma":0.0003072262,"threshold_uncertainty_score":0.99965763},"labels":[],"label_agreement":null},{"id":"W4407081442","doi":"10.1080/1750743x.2025.2455922","title":"Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer","year":2025,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Thyroid cancer; Follicular phase; Medicine; Follicular cell; Cancer research; Follicular thyroid cancer; Thyroid; Oncology; Immunology; Cancer; Internal medicine; Papillary thyroid cancer","score_opus":0.04647064221397133,"score_gpt":0.32639970456052403,"score_spread":0.2799290623465527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407081442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00272792,0.99250036,0.0000065974377,0.0001857582,0.0002331088,0.002987147,0.000046989044,0.000016997206,0.0012950972],"genre_scores_gemma":[0.0022249757,0.9923413,0.0001057941,0.00015772069,0.0000626303,0.0047934693,0.00002787928,0.00006602625,0.00022021378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99772143,0.0002337126,0.0009209958,0.00036881142,0.0004416823,0.00031334258],"domain_scores_gemma":[0.9978275,0.00025328735,0.0005167292,0.0013210949,0.000060899474,0.000020498363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003912447,0.0004889751,0.0017086108,0.00020128366,0.00007208337,0.000020129108,0.0006795372,0.00011057513,0.00005870276],"category_scores_gemma":[0.000001911655,0.00024533813,0.0009594981,0.0007263238,0.00010004945,0.000051707786,0.00005153036,0.00033053645,0.000004396213],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013043618,0.0005556905,0.000041041047,0.006276779,0.00239283,0.000016323533,0.0012343088,0.0000050773783,0.00026905263,0.0004962707,0.000047868216,0.98853433],"study_design_scores_gemma":[0.0028181488,0.00029574748,0.00075352914,0.032441262,0.0012299813,0.000006283053,0.00085155776,0.0000010054159,0.001688285,0.0000614249,0.9596089,0.00024387432],"about_ca_topic_score_codex":0.00072851375,"about_ca_topic_score_gemma":0.00001760825,"teacher_disagreement_score":0.9882904,"about_ca_system_score_codex":0.00023593321,"about_ca_system_score_gemma":0.00024411154,"threshold_uncertainty_score":0.9999999},"labels":[],"label_agreement":null},{"id":"W4407377433","doi":"10.1080/1750743x.2025.2457931","title":"Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"McGill University; McMaster University; AstraZeneca","keywords":"Benralizumab; Asthma; Medicine; Eosinophilic; Internal medicine; Pathology; Eosinophil; Mepolizumab","score_opus":0.0220841725104322,"score_gpt":0.33048536828880365,"score_spread":0.30840119577837144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407377433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875987,0.0099046705,0.00001927684,0.0010900875,0.00006543667,0.0006740577,0.00005537197,0.000072336356,0.00052004657],"genre_scores_gemma":[0.99299353,0.0026815736,0.00025787068,0.0016098327,0.00004404721,0.00006692055,0.00024951657,0.000021221087,0.0020755015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848866,0.00021701514,0.0005871271,0.00032444476,0.00013247949,0.00025025575],"domain_scores_gemma":[0.99903816,0.00022530068,0.00015673664,0.00040585094,0.000093582246,0.00008035011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033343912,0.000173024,0.0004274616,0.00025595352,0.000044240584,0.000038766084,0.0001191281,0.00016629632,0.00004571103],"category_scores_gemma":[0.00017255684,0.00013370093,0.000114331866,0.00051263504,0.00023299053,0.00014073536,0.000035456225,0.0002098325,0.000003410624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015801121,0.0010381152,0.71876556,0.00011599188,0.00011298513,0.000024191002,0.00033727073,3.2864784e-7,0.013003726,0.000828394,0.004883754,0.25930956],"study_design_scores_gemma":[0.0050803088,0.0007390906,0.90658236,0.00028133063,0.000022776438,0.000006994083,0.00031591425,0.000051586554,0.0007139021,0.000072258415,0.08596072,0.00017275156],"about_ca_topic_score_codex":0.0007340434,"about_ca_topic_score_gemma":0.0002678491,"teacher_disagreement_score":0.25913683,"about_ca_system_score_codex":0.000061832056,"about_ca_system_score_gemma":0.00015917144,"threshold_uncertainty_score":0.54521656},"labels":[],"label_agreement":null},{"id":"W4408003542","doi":"10.1080/1750743x.2025.2464528","title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovaderm (Canada)","funders":"Amgen","keywords":"Atopic dermatitis; Medicine; Dermatology; Rocket (weapon); Engineering; Aeronautics","score_opus":0.020515252635573036,"score_gpt":0.3718269398653076,"score_spread":0.3513116872297346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408003542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883663,0.0062849177,0.0002148606,0.002901966,0.000050277053,0.0011715734,0.0000049586697,0.000036626585,0.0009685319],"genre_scores_gemma":[0.9964385,0.00025222867,0.00068016915,0.0022171757,0.000010331325,0.00014809467,0.000009054835,0.0000096035765,0.00023483654],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999148,0.00011005274,0.0003165345,0.00015437366,0.000111010675,0.00016001226],"domain_scores_gemma":[0.99936485,0.00021353377,0.000056537803,0.0002745966,0.00006044729,0.000030034207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001707222,0.000111173606,0.00027636875,0.00009112892,0.00009272169,0.000015077038,0.00009524053,0.000060695085,0.000039505325],"category_scores_gemma":[0.00012222305,0.00007873982,0.000044624885,0.00025780348,0.00007979928,0.000040419465,0.00002564907,0.00012363895,0.0000041344642],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032071695,0.0011741606,0.028630963,0.00017610427,0.00020553343,0.00002032172,0.002192983,0.000051862025,0.0019197759,0.0002891019,0.0005544741,0.96157753],"study_design_scores_gemma":[0.046494078,0.0011542864,0.9228901,0.0013682852,0.00013817457,0.00017846654,0.0005324273,0.011533613,0.005579999,0.0014553329,0.008397806,0.0002773958],"about_ca_topic_score_codex":0.000028194365,"about_ca_topic_score_gemma":0.000009845272,"teacher_disagreement_score":0.96130013,"about_ca_system_score_codex":0.000022733511,"about_ca_system_score_gemma":0.00013678118,"threshold_uncertainty_score":0.32109165},"labels":[],"label_agreement":null},{"id":"W4409178690","doi":"10.1080/1750743x.2025.2485012","title":"Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; McMaster University; Pancreas Centre (Canada); University Health Network; Kingston Health Sciences Centre; Canadian Partnership Against Cancer","funders":"Canadian Cancer Society Research Institute; AstraZeneca","keywords":"Immune system; Medicine; Immunology; Oncology; Cancer research","score_opus":0.012069763549505152,"score_gpt":0.29527718584675666,"score_spread":0.2832074222972515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409178690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840057,0.013351852,0.00009287428,0.0009635772,0.00038781404,0.00078910706,0.00021078947,0.00003843765,0.00015988086],"genre_scores_gemma":[0.99730206,0.00076004374,0.00019273383,0.0008204681,0.000026303744,0.000042742307,0.00020810176,0.000028914985,0.00061861053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975007,0.00026211055,0.0009864919,0.00042823766,0.0005504226,0.00027199642],"domain_scores_gemma":[0.99735975,0.00037906485,0.0004213465,0.0016342606,0.00016214678,0.000043437412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009790375,0.00027284812,0.0009430433,0.0010258108,0.00006242008,0.000016491102,0.0005383129,0.0001714846,0.00011699402],"category_scores_gemma":[0.00019224104,0.0002247218,0.00046692367,0.0021809347,0.0002246307,0.00007453616,0.00012858352,0.00021418525,0.0000023382897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043664318,0.00094946113,0.0009871456,0.00017390875,0.014180031,0.000010317421,0.0011662347,0.000009600095,0.8600155,0.000048594186,0.00069253304,0.07810236],"study_design_scores_gemma":[0.0069011576,0.001857529,0.33549947,0.0005395888,0.0020426635,0.0000021480914,0.00017551977,0.000093751434,0.6441413,0.000011212905,0.008563307,0.00017236055],"about_ca_topic_score_codex":0.0005498447,"about_ca_topic_score_gemma":0.000017991973,"teacher_disagreement_score":0.33451232,"about_ca_system_score_codex":0.00014787311,"about_ca_system_score_gemma":0.00039805289,"threshold_uncertainty_score":0.9163889},"labels":[],"label_agreement":null},{"id":"W4409810942","doi":"10.1080/1750743x.2025.2491295","title":"Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects","year":2025,"lang":"en","type":"review","venue":"Immunotherapy","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Myasthenia gravis; Medicine; Intensive care medicine; Immunology","score_opus":0.023138706098924072,"score_gpt":0.35242130160104707,"score_spread":0.329282595502123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409810942","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004103998,0.9923349,0.00004466214,0.00047668634,0.0004900024,0.005424765,0.00021828002,0.00012920567,0.0008404696],"genre_scores_gemma":[0.000004964672,0.98555696,0.001116535,0.00023145578,0.0011112927,0.0018299895,0.0003163728,0.00014773312,0.009684678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99790674,0.00006788222,0.0006598482,0.00072734687,0.00016576631,0.00047240648],"domain_scores_gemma":[0.9985042,0.00013995751,0.0002840226,0.0008709367,0.000091602196,0.00010924085],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011683187,0.0008375637,0.0028808317,0.0002512531,0.00017219681,0.00008534348,0.00017744803,0.0005066598,0.00007296911],"category_scores_gemma":[0.000009089426,0.0005400686,0.001027803,0.00030396855,0.0000822963,0.000046100176,0.000028667662,0.00024268076,0.00001992237],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002853471,0.00017395588,0.000004263172,0.010085658,0.0011318583,0.000022151391,0.0002856531,3.0854261e-9,0.0000040381988,0.004957768,0.00039445906,0.98265487],"study_design_scores_gemma":[0.0043665105,0.0014748077,0.000020615356,0.010013416,0.0012776509,0.00042858903,0.00002909003,0.0000010802576,0.000006659188,0.0004008418,0.98156226,0.00041851183],"about_ca_topic_score_codex":0.000039383947,"about_ca_topic_score_gemma":0.000006645416,"teacher_disagreement_score":0.9822363,"about_ca_system_score_codex":0.00027970882,"about_ca_system_score_gemma":0.00064910966,"threshold_uncertainty_score":0.9997051},"labels":[],"label_agreement":null},{"id":"W4410303297","doi":"10.1080/1750743x.2025.2493039","title":"Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Medac; Cilag; Mylan; Celgene; Biogen; Gilead Sciences; Chugai Pharmaceutical; Celltrion; Sanofi; Eli Lilly and Company; AstraZeneca; Edwards Lifesciences; Amgen","keywords":"Biosimilar; Etanercept; Medicine; Plain language; Pharmacology; Internal medicine; Intensive care medicine; Oncology; Physical therapy; Rheumatoid arthritis; Linguistics","score_opus":0.02248146023747329,"score_gpt":0.35650275953216726,"score_spread":0.334021299294694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410303297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931316,0.0027823197,0.000066367385,0.001382366,0.0000707864,0.0010471743,0.000026178532,0.00005848519,0.0014347733],"genre_scores_gemma":[0.9974996,0.00034582993,0.0002621873,0.0009272581,0.000008791638,0.00009521981,0.000054490272,0.000024324076,0.0007822963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972142,0.0014745125,0.00040658147,0.0004046139,0.00008234615,0.00041775344],"domain_scores_gemma":[0.9985458,0.0006675157,0.00011457755,0.0006256286,0.000025108584,0.00002135678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061661477,0.00034350625,0.000655392,0.00033486157,0.00019827603,0.00011789329,0.00037566538,0.00012222845,0.00013751896],"category_scores_gemma":[0.000015223756,0.00017478362,0.00007398703,0.00093859853,0.00021935752,0.0001659757,0.00002661186,0.00033490622,0.0000039248243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00484022,0.008751292,0.85918045,0.000061501225,0.0013210967,0.00019659573,0.026291128,0.00003874691,0.019728815,0.00047729825,0.00029135402,0.07882151],"study_design_scores_gemma":[0.007919597,0.0021812355,0.96664375,0.00035469185,0.00014066049,0.000015215741,0.019785205,0.00007198228,0.0012258055,0.00006663934,0.0012644043,0.00033082438],"about_ca_topic_score_codex":0.006525782,"about_ca_topic_score_gemma":0.04162815,"teacher_disagreement_score":0.1074633,"about_ca_system_score_codex":0.00020774918,"about_ca_system_score_gemma":0.00017212219,"threshold_uncertainty_score":0.98650736},"labels":[],"label_agreement":null},{"id":"W4411260891","doi":"10.1080/1750743x.2025.2518913","title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; Population Health Research Institute; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Head and neck; Toxicity; Basal cell; Oncology; Head and neck squamous-cell carcinoma; Radiation therapy; Internal medicine; Carcinoma; Head and neck cancer; Surgery; Cancer; Immunotherapy","score_opus":0.013062482689831033,"score_gpt":0.2701643034079915,"score_spread":0.2571018207181605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411260891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929902,0.0048557944,0.00011869785,0.0001347304,0.00013274106,0.0005368319,0.000010162223,0.000023889943,0.0011969316],"genre_scores_gemma":[0.99832207,0.00013420699,0.0003862734,0.0005703162,0.000008872521,0.000031261832,0.000010417841,0.000012585267,0.0005239721],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989254,0.000054144668,0.00041690716,0.00024041563,0.0001627391,0.00020038182],"domain_scores_gemma":[0.99945045,0.000053861586,0.00010948733,0.00028605817,0.000071448325,0.00002869949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012166718,0.0001613217,0.00034775084,0.0001976856,0.000052380998,0.000014407014,0.0000895707,0.00006428218,0.00008069468],"category_scores_gemma":[0.000025888447,0.00014461047,0.00008395285,0.00038744998,0.00024170913,0.00011624022,0.000018735926,0.00009780186,0.000003015882],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009619029,0.002403673,0.121115915,0.0002842371,0.00007554504,0.000015422484,0.00551717,0.0000063295665,0.8080187,0.000064666085,0.0001601826,0.05271912],"study_design_scores_gemma":[0.036322307,0.0033787428,0.6431766,0.0004954142,0.000056124758,0.000014666296,0.0007005959,0.00055919937,0.30856353,0.000079081175,0.0062779887,0.0003757212],"about_ca_topic_score_codex":0.00062690646,"about_ca_topic_score_gemma":0.000053252676,"teacher_disagreement_score":0.5220607,"about_ca_system_score_codex":0.00019080463,"about_ca_system_score_gemma":0.00012576443,"threshold_uncertainty_score":0.5897044},"labels":[],"label_agreement":null},{"id":"W4411899191","doi":"10.1080/1750743x.2025.2527574","title":"Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?","year":2025,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; McMaster University","funders":"","keywords":"Medicine; Melanoma; Dissection (medical); Lymph node; Immunotherapy; Neoadjuvant therapy; Surgery; Pathology; Immune system; Internal medicine; Immunology; Cancer research; Cancer","score_opus":0.007626434994813059,"score_gpt":0.28104288107949543,"score_spread":0.27341644608468235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411899191","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.043576453,0.022038043,0.01576672,0.0058096414,0.8921977,0.013628627,0.00031804995,0.0006563888,0.0060083717],"genre_scores_gemma":[0.16233817,0.03002331,0.0023087433,0.016868874,0.6317231,0.01112309,0.0029976063,0.0013059347,0.1413112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965455,0.00021659411,0.00077045645,0.00087793835,0.00090260117,0.00068692176],"domain_scores_gemma":[0.99714196,0.0007914173,0.00035561353,0.001408231,0.0002497479,0.00005305255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007039954,0.0007689403,0.0010481182,0.0005047637,0.00025230096,0.00025207907,0.00060304184,0.00074440625,0.0001332215],"category_scores_gemma":[0.000056243905,0.0005079533,0.00042399674,0.00059070066,0.00013747034,0.00008323038,0.000031259624,0.0008829833,0.000021584478],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031598862,0.002200331,0.00071078574,0.0013733157,0.004146915,0.00038310405,0.0055796443,0.000048544047,0.011450932,0.0008642706,0.5686395,0.37300375],"study_design_scores_gemma":[0.011500625,0.0015662345,0.0017189085,0.0005909169,0.00020502073,0.00011608275,0.00058484543,0.00015864873,0.0006472278,0.00022061336,0.98214316,0.0005477184],"about_ca_topic_score_codex":0.0006018576,"about_ca_topic_score_gemma":0.0002006964,"teacher_disagreement_score":0.41350362,"about_ca_system_score_codex":0.00064141385,"about_ca_system_score_gemma":0.00056805345,"threshold_uncertainty_score":0.9997372},"labels":[],"label_agreement":null},{"id":"W4413876847","doi":"10.1080/1750743x.2025.2545172","title":"Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Cardiovascular Prevention and Rehabilitation; Probity Medical Research","funders":"","keywords":"Atopic dermatitis; Medicine; Antibody; Immunology; Dermatology","score_opus":0.017410696122824466,"score_gpt":0.38352179729230657,"score_spread":0.3661111011694821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413876847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98614657,0.011587197,0.0003685459,0.00020984223,0.00020999124,0.0011324402,0.00007627359,0.000070078844,0.00019904399],"genre_scores_gemma":[0.99681777,0.0005902151,0.00024860678,0.0014461431,0.00009425116,0.000042680706,0.00007623338,0.000026727716,0.00065736356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998674,0.00012917219,0.00056567596,0.00026990214,0.00015793034,0.00020335824],"domain_scores_gemma":[0.9990051,0.0001706967,0.00012516089,0.0005224736,0.00010246645,0.000074094256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029594163,0.00016936382,0.00054196815,0.0001264216,0.000088147935,0.000019852341,0.00015704067,0.00010845417,0.000027545608],"category_scores_gemma":[0.0000636781,0.00013373794,0.00020059591,0.00018079484,0.00012208837,0.00008226608,0.000024386476,0.00012413113,0.0000034798609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008115522,0.004733035,0.6816909,0.00030352306,0.0006029744,0.00010185464,0.0017725365,0.000001295084,0.027320232,0.00010993404,0.0009212282,0.281631],"study_design_scores_gemma":[0.011040906,0.0024036649,0.9521655,0.00037757232,0.00015634655,0.000006256467,0.004138444,0.00011027003,0.0051179957,0.000043500724,0.024256656,0.00018289697],"about_ca_topic_score_codex":0.00006277976,"about_ca_topic_score_gemma":0.000022628254,"teacher_disagreement_score":0.2814481,"about_ca_system_score_codex":0.000020105952,"about_ca_system_score_gemma":0.00022240954,"threshold_uncertainty_score":0.5453675},"labels":[],"label_agreement":null},{"id":"W4415765951","doi":"10.1080/1750743x.2025.2578164","title":"Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials","year":2025,"lang":"en","type":"article","venue":"Immunotherapy","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Pancreas Centre (Canada); Queen's University; McMaster University; Juravinski Cancer Centre; Occupational Cancer Research Centre; Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; AstraZeneca","keywords":"Serotonergic; Pooled analysis; Context (archaeology); Clinical trial; Meta-analysis; Patient data; Cancer; Immune system","score_opus":0.04188281269778614,"score_gpt":0.3426528544300924,"score_spread":0.30077004173230626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415765951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95172936,0.04194423,0.000025760233,0.0011287155,0.00083559623,0.0025141696,0.0017459448,0.00003584466,0.000040376628],"genre_scores_gemma":[0.9924833,0.0047559175,0.00012672995,0.0008305486,0.00024628965,0.00037949378,0.0006697822,0.000061845625,0.00044610462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9921398,0.0033137447,0.002623241,0.00067039684,0.0007680324,0.0004847875],"domain_scores_gemma":[0.98883164,0.0073274695,0.0014644639,0.0019966117,0.00021625974,0.000163541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0063748267,0.00047472678,0.003776747,0.001885799,0.00012113756,0.000052108382,0.00074909907,0.0003215138,0.0004390086],"category_scores_gemma":[0.004398801,0.00038223152,0.0011306223,0.0018606333,0.00019057283,0.000119047276,0.000098733784,0.00032749202,0.0000047155627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10005918,0.0007580919,0.0011634029,0.0002331559,0.028010711,0.000037420545,0.0033028778,0.00004334644,0.736161,0.000028179928,0.0015031369,0.1286995],"study_design_scores_gemma":[0.028929165,0.00264293,0.36203387,0.003421411,0.015119958,0.0000034739608,0.0008510801,0.00031414893,0.5509484,0.000051513805,0.035062924,0.00062117126],"about_ca_topic_score_codex":0.19699593,"about_ca_topic_score_gemma":0.011479722,"teacher_disagreement_score":0.36087045,"about_ca_system_score_codex":0.00043723368,"about_ca_system_score_gemma":0.0020181881,"threshold_uncertainty_score":0.99986297},"labels":[],"label_agreement":null}]}